ClinicalTrials.gg
CompletedNCT03583697Updated Jun 13, 2024Results posted

A Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondroplasia

A Phase 2 interventional study of BMN 111 and Placebo in Achondroplasia, sponsored by BioMarin Pharmaceutical. Completed at 16 sites in 4 countries. Open to participants aged Up to 59 Months. Per ClinicalTrials.gov, last updated 2024-06-13.

Sponsored by BioMarin Pharmaceutical · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
Up to 59 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Achondroplasia by BioMarin Pharmaceutical — 2 open to participants now, 6 under way, 2 of them phase 3. Achondroplasia · BioMarin Pharmaceutical.

Enrollment
4th of 10
75 · median 74
Started
2018
the only one that year
Phase 2
5 of 14
none open now
Registered
8th of 14
by date

Among the 14 studies in Achondroplasia by BioMarin Pharmaceutical, this one is the 4th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2018, is one of 5 in phase 2, and was the 8th registered.

Achondroplasia

47 studies on the registry are indexed under Achondroplasia; 13 are open to participants now.

Browse Achondroplasia studies →

Open to participants now

2 of the 14 studies in Achondroplasia by BioMarin Pharmaceutical are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 9 Achondroplasia studies recruiting now, 2 set no upper age limit and 7 stop at 75 or younger; 9 take children under 18; none take healthy volunteers.

This study: Up to 59 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Achondroplasia by BioMarin Pharmaceutical, or all of them as a file.
02

Study summary

Study 111-206 is a Phase 2 randomized, double-blind, placebo-controlled clinical trial of BMN 111 in infants and young children with a diagnosis of achondroplasia.

03

Conditions studied

  • Achondroplasia

Keywords

  • Dwarfism
  • Bone Diseases
  • Bone Diseases, Developmental
  • ACH
  • Natriuretic Peptide, C-Type
  • Musculoskeletal Diseases
  • Natriuretic Agents
  • Physiological Effect of Drugs
  • Skeletal Dysplasias
  • Genetic Diseases, Inborn
  • Osteochondrodysplasias
04

Who can participate

Ages eligible
Up to 59 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of achondroplasia (ACH), confirmed by genetic testing. If subjects had previous genetic testing, subjects must have a lab report from a certified laboratory with the study specific mutation documented.
  2. Age 0 to \< 60 months, at study entry (Day 1)
  3. Cohort 1 and 2 subjects must have at least a 6-month period of pretreatment growth assessment in Study 111 901 immediately before screening, and have one documented measurement of height/body length a minimum of 6 months prior to the screening visit for 111-206. Cohort 3 subjects must have a minimum of 3 months of observation prior to treatment. This observational period can be obtained either (1) via prior enrollment in Study 111-901 or (2) via enrollment in this Study 111 206 for a minimum of 3 months of non-treatment observation prior to commencement of treatment.
  4. Parent(s) or guardian(s) (and the subjects themselves, if required by local regulations or ethics committee) are willing and able to provide written, signed after the nature of the study has been explained and prior to performance of any research-related procedure
  5. Willing and able to perform all study procedures as physically possible
  6. Parent(s) or caregiver(s) are willing to administer daily injections to the subjects and complete the required training

Exclusion criteria

Exclusion Criteria:

  1. Have hypochondroplasia or short-stature condition other than achondroplasia (e.g., trisomy 21, pseudoachondroplasia, etc.)
  2. Subject weighs \< 5.0 kg (Cohort 1 and 2) or \< 4.0 kg (Cohort 3)
  3. Have any of the following:

    • Hypothyroidism or hyperthyroidism
    • Insulin-requiring diabetes mellitus
    • inflammatory disease (including celiac disease, systemic lupus erythematosus, juvenile dermatomyositis, scleroderma, etc.)
    • Inflammatory bowel disease
    • Autonomic neuropathy
  4. Have a history of any of the following:

    • Renal insufficiency defined as serum creatinine > 2 mg/dL
    • Chronic anemia or \<10.0 g/dL (based on screening clinical laboratory testing)
    • Baseline systolic blood pressure (BP) below age and gender specified normal range or recurrent symptomatic hypotension (defined as episodes of low BP generally accompanied by symptoms e.g., dizziness, fainting) or recurrent symptomatic orthostatic hypotension
    • Cardiac or vascular disease, including the following

      • Cardiac dysfunction (abnormal echocardiogram determined to be by principal investigator PI and medical monitor) at Screening Visit
      • Hypertrophic cardiomyopathy
      • Pulmonary hypertension
      • Congenital heart disease with ongoing cardiac dysfunction
      • Cerebrovascular disease
      • Aortic insufficiency or other clinically significant valvular dysfunction
      • Clinically significant atrial or ventricular arrhythmias
  5. Have a clinically significant finding or arrhythmia that indicates abnormal cardiac function or conduction or Fridericia's interval (QTc-F) >450 msec on screening
  6. Have evidence of cervicomedullary compression (CMC) likely to require surgical intervention within 60 days of Screening as determined by the Investigator based on the following assessments

    • Physical exam (e.g., neurologic findings of clonus, opisthotonus, exaggerated reflexes, dilated facial veins)
    • Polysomnography (e.g., severe central sleep apnea)
    • MRI indicating presence of severe CMC or spinal cord damage
  7. Have an unstable medical condition likely to require surgical intervention in the next 6 months, or planned spine or long-bone surgery (i.e., surgery involving significant disruption of bone cortex) during the study period
  8. Have documented uncorrected Vitamin D deficiency: 25(OH)D \<=15 ng/mL (37.5 nmol/L)
  9. Require any other product prior to completion of the study period
  10. Have received another investigational product or investigational medical device within 30 days prior to the Screening visit
  11. Have used any other investigational product or investigational medical device for the treatment of achondroplasia or short stature at any time
  12. Require current chronic therapy with antihypertensive medication or any medication that, in the investigator's judgment, may compromise the safety or ability of the subject to participate in this clinical study (Table 9.3.5.1)
  13. Have been treated with growth hormone, insulin-like growth factor 1 (IGF-1), or anabolic steroids in the 6 months prior to screening, or long-term treatment (>3 months) at any time
  14. Have had regular long-term treatment (> 1 month) with oral (low-dose ongoing inhaled steroid for asthma, or intranasal steroids, are acceptable) in the 12 months prior to screening
  15. Have ever had cervicomedullary decompression surgery (Cohorts 2 and 3 only), spine or long-bone surgery (i.e., surgery involving disruption of bone cortex) or have ever had bone-related surgery with chronic complications

    NOTE: Subjects with prior cervicomedullary decompression may be allowed into Cohort 1 only after discussion and agreement with Medical Monitor.

  16. Have ever had limb-lengthening surgery or plan to have limb-lengthening surgery during the study period
  17. Have had a fracture of the long bones or spine within 6 months prior to screening
  18. Have (AST) or alanine aminotransferase (ALT) or total greater than (ULN) at screening (except for subjects with a known history of Gilberts or newborns entering screening in Cohort 3)
  19. Have evidence of severe untreated sleep apnea; or have newly initiated sleep apnea treatment (eg, Continuous positive airway pressure (CPAP) or sleep apnea-mitigating surgery) in the 2 months prior to screening
  20. Have current , history of malignancy, or currently under work-up for suspected malignancy
  21. Have known to BMN 111 or its
  22. Have a history of hip surgery or severe hip dysplasia
  23. Have a history of clinically significant hip injury in the 30 days prior to screening
  24. Have a history of slipped capital femoral epiphysis or avascular necrosis of the femoral head
  25. Have abnormal findings on baseline clinical hip exam or imaging assessments that are determined to be clinically significant as determined by the Investigator
  26. Have a condition or circumstance that, in the view of the Investigator, places the subject at high risk for poor treatment compliance or for not completing the study
  27. Have any concurrent disease or condition that, in the view of the Investigator, would interfere with study participation or safety evaluations, for any reason

Inclusion Criteria for Cohort 3 Observation Period

  1. Parent(s) or guardian(s) willing and able to provide signed after the nature of the study has been explained and prior to performance of any research-related procedure. Also, willing and able to provide written assent (if applicable) after the nature of the study has been explained and prior to performance of any research-related procedure.
  2. Birth to \<= 3 months of age at study entry.
  3. Have ACH, documented by genetic testing
  4. Are willing and able to perform all study procedures as physically possible

Exclusion Criteria for Cohort 3 Observation Period

  1. Have hypochondroplasia or short stature condition other than ACH (e.g., trisomy 21, pseudoachondroplasia)
  2. Have any of the following disorders:

    • Hypothyroidism
    • Insulin-requiring diabetes mellitus
    • Autoimmune inflammatory disease (including celiac disease, lupus (SLE), juvenile dermatomyositis, scleroderma, and others)
    • Inflammatory bowel disease
    • Autonomic neuropathy
  3. Have an unstable clinical condition likely to lead to intervention during the course of the study, including progressive cervical medullary compression
  4. Have a history of any of the following:

    • Renal insufficiency
    • Anemia
  5. Have a history of cardiac or vascular disease, including the following:

    • Cardiac dysfunction
    • Hypertrophic cardiomyopathy
    • Congenital heart disease
    • Cerebrovascular disease, aortic insufficiency
    • Clinically significant atrial or ventricular arrhythmias
  6. Current treatment with antihypertensive medications, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers, diuretics, beta-blockers, calcium-channel blockers, cardiac glycosides, systemic anticholinergic agents, any medication that may impair or enhance compensatory tachycardia, drugs known to alter renal function that is expected to continue for the duration of the study
  7. Have had regular long-term treatment (> 1 month) with oral corticosteroids (low-dose ongoing inhaled steroid for asthma is acceptable) in the previous 3 month
  8. Concomitant medication that prolongs the QT/QTc interval within 14 days or 5 half-lives, whichever is longer, before the Screening visit
  9. Have used any other investigational product or investigational medical device for the treatment of ACH or short stature
  10. Planned or expected bone-related surgery (ie. surgery involving disruption of bone cortex), during the study period.
  11. Planned or expected to have limb-lengthening surgery during the study period.
  12. Have any condition that, in the view of the Investigator, places the subject at high risk of poor compliance with the visit schedule or of not completing the study.
  13. Concurrent disease or condition that, in the view of the Investigator, would interfere with study participation
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
75 participants (actual)

Study arms

  • Experimental
    Active BMN111

    Subcutaneous injection of 15 μg/kg/day and/or 30 μg/kg/day of BMN111 daily.

    Drug: BMN 111

  • Placebo comparator
    Placebo

    Daily subcutaneous injection of placebo

    Drug: Placebo

Interventions

  • Subcutaneous injection of 15 μg/kg/day and/or 30 μg/kg/day of BMN 111 daily, subject to adjustment per protocol

    Also known as: Vosoritide, Modified recombinant human C-type natriuretic peptide

  • DrugPlacebo

    Subcutaneous injection of 15 μg/kg of placebo daily, Subject to adjustment per protocol

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs) by Severity Grade and Study Drug Treatment-emergent Adverse Events (TEAEs)

    A treatment-emergent Adverse Events (TEAE) is any Adverse Events that newly appeared, increased in frequency or worsened in severity following initiation of study drug administration. A severity grade was defined by the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. As per CTCAE, Grade 1 scales as Mild; Grade 2 scales as Moderate; Grade 3 scales as severe or medically significant but not immediately life threatening; Grade 4 scales as life-threatening consequences; and Grade 5 scales as death related to AE. Safety Population includes all sentinel and randomized participants in the FAS who received at least one dose of vosoritide or placebo in this study. Serious adverse event (SAE)

    Time frame: Up to Week 56 (Safety Follow-Up +/-7d)

  2. Change From Baseline in Height Z-score at Week 52.

    Z-Scores were derived using age-sex specific reference data (means and SDS) for average stature children per the Centers for Disease Control and Prevention. A height Z score of 0 would indicate that the subject's height is equal to the mean height for the average stature population of the same sex and age. A positive height Z score indicates that the subjects height is above the mean height for the average stature population of the same sex and age, whilst a negative height Z score indicates that the subjects height is below the mean height for the average stature population of the same sex and age. To conclude if the height Z score increases then this means the height deficit has decreased. standard deviation score (SDS). The primary efficacy analysis population was the subset of randomized participants in the FAS.

    Time frame: Baseline to Week 52

Secondary outcomes

  1. Change From Baseline in Height at Week 52

    As a general rule, standing height/sitting height was used if participants were aged \>= 24 months at baseline. Body length/crown to rump was used if participants were aged \< 24 months at baseline. If body length was not measured and standing height was available, standing height was used.

    Time frame: Baseline to Week 52

  2. Change From Baseline in Annualized Growth Velocity (AGV) at Week 52

    AGV was derived over 12-month intervals starting from the baseline visit. Annualized growth velocity (AGV) = Standing Height at Date 2 - Standing Height at Date 1/Interval Length (Days) x 365.25. Difference in LS means were obtained from an analysis of covariance model.

    Time frame: Baseline to Week 52

  3. Change From Baseline in Upper to Lower Body Segment Ratio at Week 52

    Upper to Lower Body ratio=Sitting Height / (Standing Height - Sitting Height).

    Time frame: Baseline to Week 52

  4. Change From Baseline in Other Growth Measures (Upper Body Length, Head Circumference, Arm Span, Upper Arm Length, Lower Arm Length, Lower Body Length, Upper Leg Length, Knee to Heel Length, and Tibial Length) at Week 52

    Change from baseline in other growth measures (upper body length, head circumference, arm span, upper arm length, lower arm (Forearm) length, Lower Body Length, Upper Leg Length (Thigh), knee to heel length, and tibial length) at Week 52. Participants aged \<24 months, body length and crown to rump length take precedence over standing height and sitting height. Participants aged \<24 months at baseline and \>=24 months at Week 52, body length and crown to rump length take precedence.

    Time frame: Baseline to Week 52

  5. Change From Baseline in Other Body Proportion Ratios (Arm Span to Height Ratio, Upper Arm Length to Lower Arm [Forearm] Length Ratio, Upper Leg Length [Thigh] to Knee to Heel Length Ratio, and Upper Leg Length (Thigh) to Tibial Length Ratio) at Week 52

    For Height: subjects aged \< 24 months, body length takes precedence over standing height. Subjects aged \< 24 months at baseline and \>= 24 months at Week 52, body length takes precedence.

    Time frame: Baseline to Week 52

  6. Change From Baseline in Body Mass Index (BMI) at Week 52

    Body Mass Index (BMI): For height used for BMI calculation, participants aged \< 24 months, body length takes precedence over standing height. Participants aged \< 24 months at baseline and \>= 24 months at Week 52, body length takes precedence.

    Time frame: Baseline to Week 52

  7. Change From Baseline in BMI Z-score at Week 52

    The body mass index (BMI) Z-score represents the participant's BMI converted to an age and sex appropriate standard deviation score (SDS) by comparison with an average stature reference population. The weight Z-score of 0 represents the mean BMI for age and sex of the reference population. A positive BMI Z-score means BMI is above the mean BMI for the average stature population of the same sex and age and a negative BMI Z-Score means BMI is below the mean BMI for the average stature population of the same sex and age. BMI Z-scores are derived only for participants aged 24 months or older, the change from baseline to Week 52 in BMI Z-score is summarized for Cohort 1 only as no participants in Cohort 2 or Cohort 3 were 24 months at baseline.

    Time frame: Baseline to Week 52

  8. Change From Baseline in Weight Z-score at Week 52

    The weight Z-score represents the participant's weight converted to an age and sex appropriate standard deviation score (SDS) by comparison with an average stature reference population. The weight Z-score of 0 represents the mean weight for age and sex of the reference population. A positive weight Z-score means weight is above the mean weight for the average stature population of the same sex and age and a negative weight Z-Score means weight is below the mean weight for the average stature population of the same sex and age.

    Time frame: Baseline to Week 52

  9. Change From Baseline in Infant Toddler Quality of Life (ITQoL) Scores at Week 52

    97(ITQOL) item full-length version was used. For each concept, item responses are scored, summed, \& transformed on a scale from 0(worst health) to 100(best health).

    Time frame: Baseline to Week 52

  10. Change From Baseline in ITQoL-Behavior Scores at Week 52

    97(ITQOL) item full-length version was used. For each concept, item responses are scored, summed, \& transformed on a scale from 0(worst health) to 100(best health). The number of subjects assessed in Cohort 3 Placebo is 0 as assessment was not done or overall score could not be derived because no more than half assessments were done at Screening/ baseline. Hence, Mean and Standard Deviation (SD) are not applicable. Note: For each variable, there are different numbers of individual questions. The variable can only be derived if at least half of the questions were completed.

    Time frame: Baseline to Week 52

  11. Change From Baseline in ITQoL-Global Behavior Scores at Week 52

    97(ITQOL) item full-length version was used. For each concept, item responses are scored, summed, \& transformed on a scale from 0(worst health) to 100(best health). A higher score indicates better global behaviour. The number of subjects assessed in Cohort 3 Placebo is 0 as assessment was not done or overall score could not be derived because no more than half assessments were done at Screening/ baseline. Hence, Mean and Standard Deviation (SD) are not applicable. Note: For each variable, there are different numbers of individual questions. The variable can only be derived if at least half of the questions were completed.

    Time frame: Baseline to Week 52

  12. Change From Baseline in ITQoL-Getting On With Other Score at Week 52

    97(ITQOL) item full-length version was used. For each concept, item responses are scored, summed, \& transformed on a scale from 0(worst health) to 100(best health). A higher score indicates better global health perceptions. The number of subjects assessed in Cohort 3 Placebo and Cohort 3 vosoritide are 0 as assessment was not done or overall score could not be derived because no more than half assessments were done at Screening/baseline. Hence, Mean and Standard Deviation (SD) are not applicable. Note: For each variable, there are different numbers of individual questions. The variable can only be derived if at least half of the questions were completed.

    Time frame: Baseline to Week 52

  13. Change From Baseline in ITQoL-Health Score at Week 52

    97(ITQOL) item full-length version was used. For each concept, item responses are scored, summed, \& transformed on a scale from 0(worst health) to 100(best health). A higher score indicates better global change in health. The number of subjects assessed in Cohort 3 Placebo is 0 as assessment was not done or overall score could not be derived because no more than half assessments were done at Screening/ baseline. Hence, Mean and Standard Deviation (SD) are not applicable. Note: For each variable, there are different numbers of individual questions. The variable can only be derived if at least half of the questions were completed.

    Time frame: Baseline to Week 52

  14. Change From Baseline in Functional Independence Measure for Children (WeeFIM-II) Score at Week 52

    The Pediatric Functional Independence Measure-II (WeeFIM®-II) is designed to measure functional independence of children between the ages of 6 months \& 18 yrs who have physical or general developmental limitations. The WeeFIM-II is comprised of 3 domains that are rated by clinicians based on information obtained from parents/caregivers (self-care \[score range 8 to 56\], mobility \[score range 8 to 35\], \& cognition \[score range 8 to 35\]) \& provides a total score between 18 (worst) \& 126 (Best). Higher score reflects higher level of independence. Performance of a child on each of individual items within WeeFIM is assigned to one of seven levels on an ordinal scale that represent function from complete \& modified independence (levels 7 \& 6) without a helping person to modified \& complete dependence (levels 5 to 1) with a helping person. Functional Independence Measure (Wee-FIM-II) is only validated in children ages 6 months to 18 yrs. Therefore results for Cohort 3 is not summarized.

    Time frame: Baseline to Week 52

  15. Change From Baseline in Bayley Scales of Infant and Toddler Development, Third Edition (BSID-III) Scores at Week 52

    BSID-III is performance-based clinician-reported outcome assessment for use in children from 1 to 42 months (1 month to 3.5 years). individually administered by the trained clinician to the participant/child Scales include Cognitive subscale, Receptive and Expressive subscales, and Gross and Fine Motor subscales. The two language scales make up a composite Language Scale score and the Gross and Fine Motor subscales yield a composite Motor Scale score. In addition, there is a Social-Emotional Scale and Adaptive Behavior Scale, which is a questionnaire read and completed by parent or caregiver. Scores range from 0 to 2, and indicate mastery (2), emerging (1) or zero (not present) Each (sub)scale yields a total raw score, standardized according to the participant's chronological age (scaled scores)

    Time frame: Baseline to Week 52

  16. Change From Baseline in Child Behaviour Checklist (CBCL) at Week 52

    The CBCL is used as a screening tool for emotional or behavioral problems, measuring initial behavior severity, tracking changes in behavioral problems over the course of treatment, and treatment planning. The CBCL 1.5-5 years old consists of 100 questions, scored on a three-point Likert scale (0=Not True (as far as you know), 1= Somewhat or Sometimes True, 2=Very True or Often True). The scores for each individual question within a domain are summed to give a domain score. The CBCL uses a normative sample to create standard scores, which are scaled so that 50 is average with a standard deviation of 10, where higher scores indicate more emotional or behavioral issues. CBCL was waived for children \< 18 months old. Therefore results for Cohort 3 is not summarized.

    Time frame: Baseline to Week 52

  17. Change From Baseline in Bilateral X-rays of Lower Extremities at Week 52

    Time frame: Baseline to Week 52

  18. Change From Baseline in Bilateral X-rays of Left/Right Tibia Bowing Angle at Week 52

    Time frame: Baseline to Week 52

  19. Change From Baseline in Bilateral X-rays of Left Femur Length (cm) to Tibia Length (cm) Ratio and Right Femur Length (cm) to Tibia Length (cm) Ratio at Week 52

    Time frame: Baseline to Week 52 End point timeframe:

  20. Change From Baseline in Bilateral X-rays of Left Tibia Length (cm) to Fibula Length (cm) Ratio & Right Tibia Length (cm) to Fibula Length (cm) Ratio at Week 52

    Time frame: Baseline to Week 52

  21. Change From Baseline in X-ray of Lumbar Spine Vertebral Ratios at Week 52

    Time frame: Baseline to Week 52

  22. Change From Baseline in X-ray of Lumbar Spine Transverse Diameter at Week 52

    Time frame: Baseline to Week 52

  23. Change From Baseline in X-ray of Lumbar Spine Sagittal Width and Week 52

    Baseline is defined as Day 1 or screening if a Day 1 assessment is not available.

    Time frame: Baseline to Week 52

  24. Change From Baseline in X-ray of Lumbar Spine Angles at Week 52

    Time frame: Baseline to Week 52

  25. Changes From Baseline in X-ray of Lumbar Spine Angle Changes: Number of Participants With an Increase in Lumbar Spine Angle at Week 52

    Percentages were calculated using the total number of subjects in the safety population (N for each treatment group) as the denominator. All increases are comparing results at Week 52 relative to the baseline assessment.

    Time frame: Baseline to Week 52

  26. MRI Parameter: Change From Baseline to Week 52 for Volume of Face, Sinus, Calvarium, Whole Brain Total Volume, Ventricles Total Volume.

    Time frame: Baseline to Week 52

  27. MRI Parameter: Percentage Change From Baseline to Week 52 for Volume of Face, Sinus, Calvarium, Whole Brain Total Volume, Ventricles Total Volume.

    Time frame: Baseline to Week 52

  28. MRI Parameter: Change From Baseline to Week 52 for Area of Foramen Magnum & Area of Spinal Cord at the Foramen Magnum Level

    Time frame: Baseline to Week 52

  29. MRI Parameter: Percentage Change From Baseline to Week 52 for Area of Foramen Magnum & Area of Spinal Cord at the Foramen Magnum Level

    Time frame: Baseline to Week 52

  30. MRI Parameter: Change From Baseline to Week 52 for Ratio of Face Volume to Calvarium, Ratio of Area of Spinal Cord to Foramen Magnum, Ratio of Face Volume to Sinus

    Time frame: Baseline to Week 52

  31. MRI Parameter: Percentage Change From Baseline to Week 52 for Ratio of Face Volume to Calvarium, Ratio of Area of Spinal Cord to Foramen Magnum, Ratio of Face Volume to Sinus

    Time frame: Baseline to Week 52

  32. Dual X Ray Absorptiometry (DEXA) Parameter: Change From Baseline to Week 52 for Whole Body Less Head Bone Mineral Content (BMC)

    Time frame: Baseline to Week 52

  33. DEXA Parameter: Change From Baseline to Week 52 of Whole Body Less Head Bone Mineral Density (BMD)

    Time frame: Baseline to Week 52

  34. DEXA Parameter: Change From Baseline to Week 52 of Whole Body BMC

    Time frame: Baseline to Week 52

  35. DEXA Parameter: Change From Baseline to Week 52 of Lumbar Spine BMC

    Time frame: Baseline to Week 52

  36. DEXA Parameter: Change From Baseline to Week 52 of Whole Body BMD

    Time frame: Baseline to Week 52

  37. DEXA Parameter: Change From Baseline to Week 52 of Lumbar Spine BMD

    Time frame: Baseline to Week 52

  38. Change From Baseline to Week 52 in Whole Body BMD Z-score

    Hologic - Discovery Horizon Whole Body BMD Z-Score. Change in whole body bone mineral density (BMD) Z-score from baseline at 52 weeks indicates whether there has been a positive or negative change in BMD using a z-score generated by converting the participants BMD to an age and sex appropriate standard deviation score (SDS) by comparison with an average stature reference population. A whole body BMD Z-score \<-2 SD can indicate low bone density in children. The Whole Body BMD (bone mineral density) z-score compares the BMD to the average bone density of people of the same age, and sex as a comparator. A Z-score less than 0 means that the participant has a lower BMD than people in the same age and sex group, and could indicate a risk of osteopenia or osteoporosis.

    Time frame: Baseline to Week 52

  39. Change From Baseline to Week 52 in Lumbar Spine BMD Z-Score

    Hologic - Discovery Horizon Lumbar Spine BMD Z-Score Change in lumbar spine bone mineral density (BMD) Z-score from baseline at 52 weeks indicates whether there has been a positive or negative change in BMD using a z-score generated by converting the participants lumbar spine BMD to an age and sex appropriate standard deviation score (SDS) by comparison with an average stature reference population. A BMD Z-score \<-2 SD can indicate low bone density in the lumbar spine in children. The Lumbar Spine BMD (bone mineral density) z-score compares the BMD in the lumbar spine to the average spinal bone density of people of the same age, and sex as a comparator. A Z-score less than 0 means that the participant has a lower BMD than people in the same age and sex group, and could indicate a risk of osteopenia or osteoporosis of the spine.

    Time frame: Baseline to Week 52

  40. Immunogenicity: Number of Participants With Incidence of Antibody Positivity at Scheduled Visits

    Number of participants with Incidence of Antibody Positivity at Scheduled Visits for : total antibody (TAb), Neutralizing antibodies (NAb), atrial natriuretic peptide (ANP), B-type Natriuretic Peptide (BNP) \& C-type natriuretic peptide (CNP). TAb Titer Positive, NAb Titer Positive, ANP Reactivity Positive, BNP Reactivity Positive \& CNP Reactivity Positive. Day 1 is the baseline assessment result taken prior to first dose of study drug. Ever Positive = the number of participants with at least one positive sample result.

    Time frame: At Day 1, Week 3, Week 13, Week 26, Week 52, & Ever Positive.

  41. Biomarker: Bone Specific Alkaline Phosphatase (BSAP) Overtime

    Time frame: At Baseline, Day 8, Week 6, Week 20, & Week 39.

  42. Biomarker: Type II Collagen C-Telopeptides Normalized for Creatinine (CTX-II)

    Time frame: Baseline to Week 52.

  43. Biomarker: Plasma Cyclic Guanosine Monophosphate (cGMP) Change From Pre-Dose to Maximum Post-Dose at Week 52

    Time frame: Week 52 Pre-Dose to Week 52 Maximum Post-Dose.

  44. Biomarker: Bone and Collagen Metabolism Biomarker Over Time-CNP Col X BM

    Laboratory results up to 30 days after study drug discontinuation were included. Baseline is the last measurement prior to the initiation of study drug.

    Time frame: At Baseline, Day 8, Week 6, Week 20, & Week 39.

  45. Change in Sleep Study Indices at Week 52

    Sleep-testing device was used to assess presence \& severity of sleep-disordered breathing by measurement of blood oxygen(O2)saturation,pulse rate,\& airflow during overnight monitoring Episodes(Epi) of sleep apnea variables summarized as: Number(No.)of epi of apnea/hr(AI);No.of epi of hypopnea/hr(HI);No.of epi of obstructive apnea hypopneas/hr(AHI);No.of epi of obstructive apneas/hr(Obstructive Apnea Index);No.of epi of central apneas/hr(CAI);No.of desaturations/hr \>=3% AHI is a marker of obstructive sleep apnea (OSA), scored as No.of apnea or hypopnea epi/hr, with AHI \<=1/hr normal, 1\< AHI\<=5 mild,5\< AHI \<=10 moderate,\& AHI\>10/hr severe OSA. CAI reflects cervical cord compression at cervical-medullary junction, \& is No. of epi of a pause in ventilation with no associated respiratory effort, with\> 5 epi/hr abnormal.O2 desaturation index measures average No. of desaturation epi/hr, defined as decrease in O2 saturation of \>=3% for at least 10sec, with(\<8/hr normal \& \>=8/hr abnormal

    Time frame: Baseline to Week 52

  46. PK Parameter: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-∞) at Day1, Week 13, Week 26, Week 39, & Week 52

    Vosoritide concentrations at 5-, 15- and 30-minute post-dose for one participant on Day 1 were not available, hence PK parameters for this participant were excluded from summary statistics. PK parameters for another participant on Day 1 obtained from extrapolation. AUC0-∞ excluded from summary statistics. PK parameters are not available for this participant at Week 13 due to unsuccessful venipuncture, and Week 26 as post-dose PK samples were not collected.

    Time frame: At Day1, Week 13, Week 26, Week 39, & Week 52.

  47. PK Parameter: Area Under the Plasma Concentration-time Curve From Time 0 to Nominal 120 Minutes Postdose (AUC 0- 120 Min) at Day 01, Week 13, Week 26, Week 39, & Week 52

    Time frame: At Day 01, Week 13, Week 26, Week 39, & Week 52

  48. PK Parameter: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of Last Measurable Concentration (AUC0-t) at Day 01, Week 13, Week 26, Week 39, & Week 52

    Time frame: At Day 01, Week 13, Week 26, Week 39, & Week 52

  49. PK Parameter: Maximum Observed Plasma Concentration (Cmax) at Day 01, Week 13, Week 26, Week 39, & Week 52

    Time frame: At Day 01, Week 13, Week 26, Week 39, & Week 52

  50. PK Parameter: Time to Reach Maximum Concentration (Tmax) at Day 01, Week 13, Week 26, Week 39, & Week 52

    Time frame: At Day 01, Week 13, Week 26, Week 39, & Week 52.

  51. PK Parameter: Apparent Clearance (CL/F) at Day 01, Week 13, Week 26, Week 39, & Week 52

    Vosoritide concentrations at 5-, 15- and 30-minute post-dose for one participant on Day 1 were not available, hence PK parameters for this participant were excluded from summary statistics. PK parameters for another participant on Day 1 obtained from extrapolation. AUC0-∞, CL/F, V/F and t1/2 excluded from summary statistics. PK parameters are not available for this participant at Week 13 due to unsuccessful venipuncture, and Week 26 as post-dose PK samples were not collected.

    Time frame: At Day 01, Week 13, Week 26, Week 39, & Week 52.

  52. PK Parameter: Apparent Volume of Distribution (Vz/F) at Day 01, Week 13, Week 26, Week 39, & Week 52

    Vosoritide concentrations at 5-, 15- and 30-minute post-dose for one participant on Day 1 were not available, hence PK parameters for this participant were excluded from summary statistics. PK parameters for another participant on Day 1 obtained from extrapolation. V/F excluded from summary statistics. PK parameters are not available for this participant at Week 13 due to unsuccessful venipuncture, and Week 26 as post-dose PK samples were not collected.

    Time frame: At Day 01, Week 13, Week 26, Week 39, & Week 52.

  53. PK Parameter: Elimination Half-life (t1/2) at Day 01, Week 13, Week 26, Week 39, & Week 52

    Vosoritide concentrations at 5-, 15- and 30-minute post-dose for one participant on Day 1 were not available, hence PK parameters for this participant were excluded from summary statistics. PK parameters for another participant on Day 1 obtained from extrapolation. AUC0-∞, CL/F, V/F and t1/2 excluded from summary statistics. PK parameters are not available for this participant at Week 13 due to unsuccessful venipuncture, and Week 26 as post-dose PK samples were not collected.

    Time frame: At Day 01, Week 13, Week 26, Week 39, & Week 52.

07

Results

Posted Jun 13, 2024

Participant flow

This was a multi-center study conducted by 16 principal investigators at 16 study centers in four countries (United States, Australia, United Kingdom and Japan).

Participant flow — Overall Study
MilestoneSentinelRandomized VosoritideRandomized Placebo
Started113232
Cohort 1: age >= 24 to < 60 months41516
Cohort 2: age >= 6 to < 24 months488
Cohort 3: age 0 to < 6 months398
Completed113131
Not completed011
Withdrew: Withdrawal by subject001
Withdrew: Ae of sudden infant death syndrome, not related010

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs) by Severity Grade and Study Drug Treatment-emergent Adverse Events (TEAEs)

A treatment-emergent Adverse Events (TEAE) is any Adverse Events that newly appeared, increased in frequency or worsened in severity following initiation of study drug administration. A severity grade was defined by the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. As per CTCAE, Grade 1 scales as Mild; Grade 2 scales as Moderate; Grade 3 scales as severe or medically significant but not immediately life threatening; Grade 4 scales as life-threatening consequences; and Grade 5 scales as death related to AE. Safety Population includes all sentinel and randomized participants in the FAS who received at least one dose of vosoritide or placebo in this study. Serious adverse event (SAE)

Time frame:
Up to Week 56 (Safety Follow-Up +/-7d)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) by Severity Grade and Study Drug Treatment-emergent Adverse Events (TEAEs)
ParticipantsSentinelRandomized VosoritideRandomized Placebo
Participants with any AE113232
Participants with any SAE036
Participants with any treatment-related AE82917
Participants with any treatment-related SAEs000
Participants with any AE of CTCAE grade >=3023
Participants who died010
PrimaryChange From Baseline in Height Z-score at Week 52.

Z-Scores were derived using age-sex specific reference data (means and SDS) for average stature children per the Centers for Disease Control and Prevention. A height Z score of 0 would indicate that the subject's height is equal to the mean height for the average stature population of the same sex and age. A positive height Z score indicates that the subjects height is above the mean height for the average stature population of the same sex and age, whilst a negative height Z score indicates that the subjects height is below the mean height for the average stature population of the same sex and age. To conclude if the height Z score increases then this means the height deficit has decreased. standard deviation score (SDS). The primary efficacy analysis population was the subset of randomized participants in the FAS.

Time frame:
Baseline to Week 52
Reported as:
Least squares mean · Z-score
Change From Baseline in Height Z-score at Week 52.
Z-scoreRandomized VosoritideRandomized PlaceboAll VosoritidePlacebo
Change From Baseline in Height Z-score at Week 52.-0.06 (-0.26 to 0.15)-0.31 (-0.48 to -0.13)0.01 (-0.15 to 0.17)-0.30 (-0.47 to -0.13)
Statistical analysis
  • Randomized Vosoritide vs Randomized Placebo · Least square mean difference (net): 0.25 · 95% CI -0.02 to 0.53
  • All Vosoritide vs Placebo · Least square mean difference (net): 0.3 · 95% CI 0.07 to 0.54
SecondaryChange From Baseline in Height at Week 52

As a general rule, standing height/sitting height was used if participants were aged \>= 24 months at baseline. Body length/crown to rump was used if participants were aged \< 24 months at baseline. If body length was not measured and standing height was available, standing height was used.

Time frame:
Baseline to Week 52
Reported as:
Least squares mean · cm
Change From Baseline in Height at Week 52
cmRandomized VosoritideRandomized PlaceboAll VosoritidePlacebo
Change From Baseline in Height at Week 528.15 (7.55 to 8.75)7.38 (6.87 to 7.89)8.41 (7.93 to 8.89)7.45 (6.95 to 7.95)
Statistical analysis
  • Randomized Vosoritide vs Randomized Placebo · Least square mean difference (net): 0.77 · 95% CI -0.02 to 1.56
  • All Vosoritide vs Placebo · Least square mean difference (net): 0.96 · 95% CI 0.26 to 1.66
SecondaryChange From Baseline in Annualized Growth Velocity (AGV) at Week 52

AGV was derived over 12-month intervals starting from the baseline visit. Annualized growth velocity (AGV) = Standing Height at Date 2 - Standing Height at Date 1/Interval Length (Days) x 365.25. Difference in LS means were obtained from an analysis of covariance model.

Time frame:
Baseline to Week 52
Reported as:
Least squares mean · cm/year
Change From Baseline in Annualized Growth Velocity (AGV) at Week 52
cm/yearRandomized VosoritideRandomized PlaceboAll VosoritidePlacebo
Change From Baseline in Annualized Growth Velocity (AGV) at Week 52-2.17 (-2.76 to -1.58)-2.95 (-3.45 to -2.45)-2.41 (-2.88 to -1.94)-3.32 (-3.81 to -2.84)
Statistical analysis
  • Randomized Vosoritide vs Randomized Placebo · Least square mean difference (net): 0.78 · 95% CI 0.02 to 1.54
  • All Vosoritide vs Placebo · Least square mean difference (net): 0.92 · 95% CI 0.24 to 1.59
SecondaryChange From Baseline in Upper to Lower Body Segment Ratio at Week 52

Upper to Lower Body ratio=Sitting Height / (Standing Height - Sitting Height).

Time frame:
Baseline to Week 52
Reported as:
Least squares mean · Ratio
Change From Baseline in Upper to Lower Body Segment Ratio at Week 52
RatioRandomized VosoritideRandomized PlaceboAll VosoritidePlacebo
Change From Baseline in Upper to Lower Body Segment Ratio at Week 52-0.20 (-0.28 to -0.13)-0.13 (-0.21 to -0.06)-0.19 (-0.25 to -0.13)-0.13 (-0.20 to -0.06)
Statistical analysis
  • Randomized Vosoritide vs Randomized Placebo · Least square mean difference (net): -0.07 · 95% CI -0.17 to 0.04
  • All Vosoritide vs Placebo · Least square mean difference (net): -0.06 · 95% CI -0.15 to 0.03
SecondaryChange From Baseline in Other Growth Measures (Upper Body Length, Head Circumference, Arm Span, Upper Arm Length, Lower Arm Length, Lower Body Length, Upper Leg Length, Knee to Heel Length, and Tibial Length) at Week 52

Change from baseline in other growth measures (upper body length, head circumference, arm span, upper arm length, lower arm (Forearm) length, Lower Body Length, Upper Leg Length (Thigh), knee to heel length, and tibial length) at Week 52. Participants aged \<24 months, body length and crown to rump length take precedence over standing height and sitting height. Participants aged \<24 months at baseline and \>=24 months at Week 52, body length and crown to rump length take precedence.

Time frame:
Baseline to Week 52
Reported as:
Mean · cm
Change From Baseline in Other Growth Measures (Upper Body Length, Head Circumference, Arm Span, Upper Arm Length, Lower Arm Length, Lower Body Length, Upper Leg Length, Knee to Heel Length, and Tibial Length) at Week 52
cmCohort 1: PlaceboCohort 1: VosoritideCohort 2: PlaceboCohort 2: VosoritideCohort 3: PlaceboCohort 3: Vosoritide
Upper body length3.04 ± 1.523.54 ± 1.815.45 ± 1.755.20 ± 1.506.58 ± 0.996.75 ± 0.86
Head Circumference0.68 ± 0.660.74 ± 0.492.29 ± 1.283.10 ± 1.455.35 ± 0.716.29 ± 0.81
Arm Span4.86 ± 1.995.82 ± 3.657.13 ± 1.597.22 ± 1.458.22 ± 1.938.99 ± 4.77
Upper Arm Length1.02 ± 1.130.77 ± 0.961.08 ± 0.931.44 ± 1.261.95 ± 1.231.44 ± 1.33
Lower Arm (Forearm) Length0.49 ± 0.960.79 ± 0.901.78 ± 0.441.57 ± 0.981.66 ± 0.821.49 ± 0.79
Lower Body Length2.41 ± 1.312.89 ± 1.992.39 ± 1.273.79 ± 1.563.86 ± 1.554.41 ± 1.53
Upper Leg Length (Thigh)0.82 ± 1.751.55 ± 1.460.38 ± 1.711.10 ± 1.421.98 ± 2.211.93 ± 1.65
Knee to Heel Length1.52 ± 0.762.21 ± 0.672.70 ± 0.752.29 ± 1.912.93 ± 0.683.12 ± 0.85
Tibial Length0.85 ± 0.691.16 ± 1.351.97 ± 1.491.99 ± 0.801.83 ± 0.881.39 ± 0.77
SecondaryChange From Baseline in Other Body Proportion Ratios (Arm Span to Height Ratio, Upper Arm Length to Lower Arm [Forearm] Length Ratio, Upper Leg Length [Thigh] to Knee to Heel Length Ratio, and Upper Leg Length (Thigh) to Tibial Length Ratio) at Week 52

For Height: subjects aged \< 24 months, body length takes precedence over standing height. Subjects aged \< 24 months at baseline and \>= 24 months at Week 52, body length takes precedence.

Time frame:
Baseline to Week 52
Reported as:
Mean · Ratio
Change From Baseline in Other Body Proportion Ratios (Arm Span to Height Ratio, Upper Arm Length to Lower Arm [Forearm] Length Ratio, Upper Leg Length [Thigh] to Knee to Heel Length Ratio, and Upper Leg Length (Thigh) to Tibial Length Ratio) at Week 52
RatioCohort 1: PlaceboCohort 1: VosoritideCohort 2: PlaceboCohort 2: VosoritideCohort 3: PlaceboCohort 3: Vosoritide
Upper Arm Length to Lower Arm(Forearm)Length Ratio0.05 ± 0.150.00 ± 0.12-0.09 ± 0.060.01 ± 0.100.02 ± 0.11-0.01 ± 0.12
Upper Leg Length(Thigh)-Knee to Heel Length Ratio-0.01 ± 0.080.01 ± 0.07-0.09 ± 0.10-0.03 ± 0.080.01 ± 0.16-0.02 ± 0.11
Upper Leg Length (Thigh) to Tibial Length Ratio0.00 ± 0.120.02 ± 0.17-0.16 ± 0.24-0.10 ± 0.070.00 ± 0.290.04 ± 0.22
Arm Span to Standing Height Ratio0.00 ± 0.020.00 ± 0.060.00 ± 0.02-0.01 ± 0.02-0.01 ± 0.04-0.02 ± 0.07
SecondaryChange From Baseline in Body Mass Index (BMI) at Week 52

Body Mass Index (BMI): For height used for BMI calculation, participants aged \< 24 months, body length takes precedence over standing height. Participants aged \< 24 months at baseline and \>= 24 months at Week 52, body length takes precedence.

Time frame:
Baseline to Week 52
Reported as:
Mean · kg/m^2
Change From Baseline in Body Mass Index (BMI) at Week 52
kg/m^2Cohort 1: PlaceboCohort 1: VosoritideCohort 2: PlaceboCohort 2: VosoritideCohort 3: PlaceboCohort 3: Vosoritide
Change From Baseline in Body Mass Index (BMI) at Week 520.20 ± 1.34-0.45 ± 0.940.55 ± 1.170.08 ± 0.750.74 ± 1.700.94 ± 1.42
SecondaryChange From Baseline in BMI Z-score at Week 52

The body mass index (BMI) Z-score represents the participant's BMI converted to an age and sex appropriate standard deviation score (SDS) by comparison with an average stature reference population. The weight Z-score of 0 represents the mean BMI for age and sex of the reference population. A positive BMI Z-score means BMI is above the mean BMI for the average stature population of the same sex and age and a negative BMI Z-Score means BMI is below the mean BMI for the average stature population of the same sex and age. BMI Z-scores are derived only for participants aged 24 months or older, the change from baseline to Week 52 in BMI Z-score is summarized for Cohort 1 only as no participants in Cohort 2 or Cohort 3 were 24 months at baseline.

Time frame:
Baseline to Week 52
Reported as:
Mean · Z-Score
Change From Baseline in BMI Z-score at Week 52
Z-ScoreCohort 1: PlaceboCohort 1: Vosoritide
Change From Baseline in BMI Z-score at Week 52-0.12 ± 0.48-0.18 ± 0.65
SecondaryChange From Baseline in Weight Z-score at Week 52

The weight Z-score represents the participant's weight converted to an age and sex appropriate standard deviation score (SDS) by comparison with an average stature reference population. The weight Z-score of 0 represents the mean weight for age and sex of the reference population. A positive weight Z-score means weight is above the mean weight for the average stature population of the same sex and age and a negative weight Z-Score means weight is below the mean weight for the average stature population of the same sex and age.

Time frame:
Baseline to Week 52
Reported as:
Mean · Z-score
Change From Baseline in Weight Z-score at Week 52
Z-scoreCohort 1: PlaceboCohort 1: VosoritideCohort 2: PlaceboCohort 2: VosoritideCohort 3: PlaceboCohort 3: Vosoritide
Change From Baseline in Weight Z-score at Week 520.14 ± 0.440.14 ± 0.420.74 ± 0.820.70 ± 0.64-0.81 ± 0.49-0.66 ± 0.77
SecondaryChange From Baseline in Infant Toddler Quality of Life (ITQoL) Scores at Week 52

97(ITQOL) item full-length version was used. For each concept, item responses are scored, summed, \& transformed on a scale from 0(worst health) to 100(best health).

Time frame:
Baseline to Week 52
Reported as:
Mean · Score on a scale
Change From Baseline in Infant Toddler Quality of Life (ITQoL) Scores at Week 52
Score on a scaleCohort 1: PlaceboCohort 1: VosoritideCohort 2: PlaceboCohort 2: VosoritideCohort 3: PlaceboCohort 3: Vosoritide
Overall Health Score3.75 ± 17.604.33 ± 15.10-5.00 ± 15.41-3.50 ± 14.15-5.00 ± 7.750.50 ± 13.01
Physical Abilities Score-6.01 ± 9.838.82 ± 23.063.36 ± 8.621.30 ± 16.052.35 ± 29.29-15.91 ± 22.74
Growth and Development Scores4.82 ± 11.624.34 ± 9.40-0.71 ± 8.751.46 ± 26.013.57 ± 6.35-3.50 ± 13.19
Pain Score-1.19 ± 20.37-1.47 ± 18.22-1.19 ± 18.90-7.64 ± 27.63-4.69 ± 27.772.50 ± 22.58
Temperament and mood Score4.79 ± 9.600.54 ± 5.400.66 ± 7.18-0.49 ± 9.78-2.43 ± 6.764.62 ± 10.48
Global health perceptions score-1.07 ± 15.432.24 ± 12.37-2.73 ± 11.29-4.55 ± 12.18-2.84 ± 13.620.50 ± 17.11
Parental impact emotional score2.04 ± 23.13-0.84 ± 8.890.51 ± 14.64-6.85 ± 11.949.82 ± 20.89-2.50 ± 19.05
Parental Impact Time Score9.52 ± 29.064.76 ± 10.78-8.05 ± 19.70-2.38 ± 35.61-10.7 ± 17.592.38 ± 14.93
Family Cohesion Score1.79 ± 13.53-1.25 ± 10.720.00 ± 15.00-7.08 ± 28.08-3.13 ± 8.84-4.50 ± 15.54
SecondaryChange From Baseline in ITQoL-Behavior Scores at Week 52

97(ITQOL) item full-length version was used. For each concept, item responses are scored, summed, \& transformed on a scale from 0(worst health) to 100(best health). The number of subjects assessed in Cohort 3 Placebo is 0 as assessment was not done or overall score could not be derived because no more than half assessments were done at Screening/ baseline. Hence, Mean and Standard Deviation (SD) are not applicable. Note: For each variable, there are different numbers of individual questions. The variable can only be derived if at least half of the questions were completed.

Time frame:
Baseline to Week 52
Reported as:
Mean · Score on a scale
Change From Baseline in ITQoL-Behavior Scores at Week 52
Score on a scaleCohort 1: PlaceboCohort 1: VosoritideCohort 2: PlaceboCohort 2: VosoritideCohort 3: VosoritideCohort 3 Placebo
Change From Baseline in ITQoL-Behavior Scores at Week 522.73 ± 23.360.37 ± 9.501.74 ± 13.60-3.39 ± 7.460.00 ± NA—
SecondaryChange From Baseline in ITQoL-Global Behavior Scores at Week 52

97(ITQOL) item full-length version was used. For each concept, item responses are scored, summed, \& transformed on a scale from 0(worst health) to 100(best health). A higher score indicates better global behaviour. The number of subjects assessed in Cohort 3 Placebo is 0 as assessment was not done or overall score could not be derived because no more than half assessments were done at Screening/ baseline. Hence, Mean and Standard Deviation (SD) are not applicable. Note: For each variable, there are different numbers of individual questions. The variable can only be derived if at least half of the questions were completed.

Time frame:
Baseline to Week 52
Reported as:
Mean · Score on a scale
Change From Baseline in ITQoL-Global Behavior Scores at Week 52
Score on a scaleCohort 1: PlaceboCohort 1: VosoritideCohort 2: PlaceboCohort 2: VosoritideCohort 3: VosoritideCohort 3: Placebo
Change From Baseline in ITQoL-Global Behavior Scores at Week 521.15 ± 21.420.29 ± 18.583.00 ± 12.55-10.56 ± 21.71-15.00 ± NA—
SecondaryChange From Baseline in ITQoL-Getting On With Other Score at Week 52

97(ITQOL) item full-length version was used. For each concept, item responses are scored, summed, \& transformed on a scale from 0(worst health) to 100(best health). A higher score indicates better global health perceptions. The number of subjects assessed in Cohort 3 Placebo and Cohort 3 vosoritide are 0 as assessment was not done or overall score could not be derived because no more than half assessments were done at Screening/baseline. Hence, Mean and Standard Deviation (SD) are not applicable. Note: For each variable, there are different numbers of individual questions. The variable can only be derived if at least half of the questions were completed.

Time frame:
Baseline to Week 52
Reported as:
Mean · Score on a scale
Change From Baseline in ITQoL-Getting On With Other Score at Week 52
Score on a scaleCohort 1: PlaceboCohort 1: VosoritideCohort 2: PlaceboCohort 2: VosoritideCohort 3: PlaceboCohort 3: Vosoritide
Change From Baseline in ITQoL-Getting On With Other Score at Week 527.78 ± 17.181.74 ± 8.882.33 ± 7.220.82 ± 5.35——
SecondaryChange From Baseline in ITQoL-Health Score at Week 52

97(ITQOL) item full-length version was used. For each concept, item responses are scored, summed, \& transformed on a scale from 0(worst health) to 100(best health). A higher score indicates better global change in health. The number of subjects assessed in Cohort 3 Placebo is 0 as assessment was not done or overall score could not be derived because no more than half assessments were done at Screening/ baseline. Hence, Mean and Standard Deviation (SD) are not applicable. Note: For each variable, there are different numbers of individual questions. The variable can only be derived if at least half of the questions were completed.

Time frame:
Baseline to Week 52
Reported as:
Mean · Score on a scale
Change From Baseline in ITQoL-Health Score at Week 52
Score on a scaleCohort 1: PlaceboCohort 1: VosoritideCohort 2: PlaceboCohort 2: VosoritideCohort 3: VosoritideCohort 3: Placebo
Change From Baseline in ITQoL-Health Score at Week 520.08 ± 0.640.13 ± 0.62-0.60 ± 1.340.33 ± 0.520.00 ± NA—
SecondaryChange From Baseline in Functional Independence Measure for Children (WeeFIM-II) Score at Week 52

The Pediatric Functional Independence Measure-II (WeeFIM®-II) is designed to measure functional independence of children between the ages of 6 months \& 18 yrs who have physical or general developmental limitations. The WeeFIM-II is comprised of 3 domains that are rated by clinicians based on information obtained from parents/caregivers (self-care \[score range 8 to 56\], mobility \[score range 8 to 35\], \& cognition \[score range 8 to 35\]) \& provides a total score between 18 (worst) \& 126 (Best). Higher score reflects higher level of independence. Performance of a child on each of individual items within WeeFIM is assigned to one of seven levels on an ordinal scale that represent function from complete \& modified independence (levels 7 \& 6) without a helping person to modified \& complete dependence (levels 5 to 1) with a helping person. Functional Independence Measure (Wee-FIM-II) is only validated in children ages 6 months to 18 yrs. Therefore results for Cohort 3 is not summarized.

Time frame:
Baseline to Week 52
Reported as:
Mean · Score on a scale
Change From Baseline in Functional Independence Measure for Children (WeeFIM-II) Score at Week 52
Score on a scaleCohort 1: PlaceboCohort 1: VosoritideCohort 2: PlaceboCohort 2: Vosoritide
WeeFIM-II Total Score11.2 ± 11.114.7 ± 17.316.2 ± 14.616.5 ± 28.1
WeeFIM : Self-Care Score6.4 ± 6.06.6 ± 7.23.7 ± 2.35.6 ± 14.1
WeeFIM: Mobility Score2.2 ± 3.44.5 ± 5.67.0 ± 7.56.7 ± 9.4
WeeFIM: Cognitive Score2.6 ± 4.03.6 ± 6.05.5 ± 7.64.2 ± 8.4
SecondaryChange From Baseline in Bayley Scales of Infant and Toddler Development, Third Edition (BSID-III) Scores at Week 52

BSID-III is performance-based clinician-reported outcome assessment for use in children from 1 to 42 months (1 month to 3.5 years). individually administered by the trained clinician to the participant/child Scales include Cognitive subscale, Receptive and Expressive subscales, and Gross and Fine Motor subscales. The two language scales make up a composite Language Scale score and the Gross and Fine Motor subscales yield a composite Motor Scale score. In addition, there is a Social-Emotional Scale and Adaptive Behavior Scale, which is a questionnaire read and completed by parent or caregiver. Scores range from 0 to 2, and indicate mastery (2), emerging (1) or zero (not present) Each (sub)scale yields a total raw score, standardized according to the participant's chronological age (scaled scores)

Time frame:
Baseline to Week 52
Reported as:
Mean · Score on a scale
Change From Baseline in Bayley Scales of Infant and Toddler Development, Third Edition (BSID-III) Scores at Week 52
Score on a scaleCohort 1: PlaceboCohort 1: VosoritideCohort 2: PlaceboCohort 2: VosoritideCohort 3: PlaceboCohort 3: Vosoritide
Motor Composite Score-2.0 ± 5.74.8 ± 11.512.0 ± 17.5-2.3 ± 12.35.4 ± 22.211.1 ± 18.1
Cognitive scaled score-1.0 ± 2.8-0.5 ± 1.73.3 ± 4.90.6 ± 3.21.5 ± 1.92.1 ± 4.4
Cognitive composite score-5.0 ± 14.1-2.5 ± 8.716.7 ± 24.73.1 ± 16.07.5 ± 9.410.6 ± 22.1
Receptive communication language scaled score-1.0 ± 0.0-1.8 ± 2.53.3 ± 4.01.0 ± 1.2-3.0 ± 2.10.7 ± 5.2
Expressive communication language scaled score2.5 ± 0.70.3 ± 1.32.8 ± 2.9-0.1 ± 2.2-1.8 ± 1.6-0.1 ± 3.3
Language sum of scaled score1.5 ± 0.7-1.5 ± 3.36.0 ± 5.21.8 ± 4.0-7.3 ± 6.4-0.3 ± 6.6
Language composite score4.5 ± 2.1-4.5 ± 9.917.8 ± 15.25.3 ± 12.1-13.4 ± 5.8-0.9 ± 19.5
Fine motor scaled score-0.5 ± 3.50.0 ± 2.91.5 ± 3.3-2.1 ± 2.52.2 ± 4.82.6 ± 2.7
Gross motor scaled score0.0 ± 5.71.0 ± 0.82.8 ± 3.21.3 ± 2.8-0.2 ± 3.10.1 ± 3.0
SecondaryChange From Baseline in Child Behaviour Checklist (CBCL) at Week 52

The CBCL is used as a screening tool for emotional or behavioral problems, measuring initial behavior severity, tracking changes in behavioral problems over the course of treatment, and treatment planning. The CBCL 1.5-5 years old consists of 100 questions, scored on a three-point Likert scale (0=Not True (as far as you know), 1= Somewhat or Sometimes True, 2=Very True or Often True). The scores for each individual question within a domain are summed to give a domain score. The CBCL uses a normative sample to create standard scores, which are scaled so that 50 is average with a standard deviation of 10, where higher scores indicate more emotional or behavioral issues. CBCL was waived for children \< 18 months old. Therefore results for Cohort 3 is not summarized.

Time frame:
Baseline to Week 52
Reported as:
Mean · Score on a scale
Change From Baseline in Child Behaviour Checklist (CBCL) at Week 52
Score on a scaleCohort 1: PlaceboCohort 1: VosoritideCohort 2: PlaceboCohort 2: Vosoritide
CBCL Pre-School : Emotionally Reactive Total-0.2 ± 1.50.1 ± 1.41.0 ± 2.01.0 ± 3.9
CBCL Pre-School : Anxious/Depressed Total0.3 ± 1.70.2 ± 1.40.0 ± 2.20.8 ± 3.1
CBCL Pre-School : Withdrawn Total-0.6 ± 1.70.6 ± 1.50.8 ± 2.2-0.2 ± 1.6
CBCL Pre-School : Somatic Complaints Total0.1 ± 1.70.3 ± 1.00.5 ± 1.01.8 ± 4.1
CBCL Pre-School : Sleep Problems Total-0.3 ± 3.20.1 ± 1.9-0.3 ± 1.71.4 ± 4.3
CBCL Pre-School : Attention Problems Total-0.1 ± 1.9-0.1 ± 1.6-0.3 ± 1.0-0.2 ± 2.0
CBCL Pre-School : Aggressive Behavior Total-1.1 ± 2.40.3 ± 4.1-0.8 ± 1.5-0.4 ± 2.7
CBCL Pre-School : Total Problems Total-3.0 ± 13.02.8 ± 11.7-2.3 ± 6.03.6 ± 23.2
SecondaryChange From Baseline in Bilateral X-rays of Lower Extremities at Week 52
Time frame:
Baseline to Week 52
Reported as:
Mean · cm
Change From Baseline in Bilateral X-rays of Lower Extremities at Week 52
cmAll VosoritidePlacebo
Left Femur Length2.29 ± 0.582.01 ± 0.62
Right Femur Length2.35 ± 0.492.20 ± 0.73
Left Fibula Length2.00 ± 0.611.97 ± 0.69
Right Fibula Length2.00 ± 0.641.89 ± 0.75
Left Tibia Length1.92 ± 0.551.69 ± 0.70
Right Tibia Length1.96 ± 0.571.68 ± 0.77
Left Distance Between Ankle Joint and Distal Growth Plate of Fibula-0.02 ± 0.230.07 ± 0.23
Right Distance Between Ankle Joint and Distal Growth Plate of Fibula-0.05 ± 0.230.05 ± 0.22
Left Lower Extremity6.02 ± 6.673.87 ± 1.56
Right Lower Extremity6.08 ± 6.544.26 ± 1.85
SecondaryChange From Baseline in Bilateral X-rays of Left/Right Tibia Bowing Angle at Week 52
Time frame:
Baseline to Week 52
Reported as:
Mean · Degrees
Change From Baseline in Bilateral X-rays of Left/Right Tibia Bowing Angle at Week 52
DegreesAll VosoritidePlacebo
Left Tibia Bowing Angle-0.97 ± 5.881.07 ± 5.38
Right Tibia Bowing Angle-2.34 ± 5.37-0.93 ± 5.54
SecondaryChange From Baseline in Bilateral X-rays of Left Femur Length (cm) to Tibia Length (cm) Ratio and Right Femur Length (cm) to Tibia Length (cm) Ratio at Week 52
Time frame:
Baseline to Week 52 End point timeframe:
Reported as:
Mean · Ratio
Change From Baseline in Bilateral X-rays of Left Femur Length (cm) to Tibia Length (cm) Ratio and Right Femur Length (cm) to Tibia Length (cm) Ratio at Week 52
RatioAll VosoritidePlacebo
Left Femur Length (cm) to Tibia Length (cm) Ratio-0.03 ± 0.06-0.05 ± 0.05
Right Femur Length (cm) to Tibia Length (cm) Ratio-0.05 ± 0.06-0.02 ± 0.03
SecondaryChange From Baseline in Bilateral X-rays of Left Tibia Length (cm) to Fibula Length (cm) Ratio & Right Tibia Length (cm) to Fibula Length (cm) Ratio at Week 52
Time frame:
Baseline to Week 52
Reported as:
Mean · Ratio
Change From Baseline in Bilateral X-rays of Left Tibia Length (cm) to Fibula Length (cm) Ratio & Right Tibia Length (cm) to Fibula Length (cm) Ratio at Week 52
RatioAll VosoritidePlacebo
Left Tibia Length (cm) to Fibula Length (cm) Ratio-0.02 ± 0.04-0.04 ± 0.04
Right Tibia Length (cm) to Fibula Length(cm) Ratio-0.02 ± 0.05-0.03 ± 0.04
SecondaryChange From Baseline in X-ray of Lumbar Spine Vertebral Ratios at Week 52
Time frame:
Baseline to Week 52
Reported as:
Mean · Ratio
Change From Baseline in X-ray of Lumbar Spine Vertebral Ratios at Week 52
RatioAll VosoritidePlacebo
Anterior Height to Medial Height Ratio (L1)-0.04 ± 0.16-0.04 ± 0.20
Anterior Height to Medial Height Ratio (L2)-0.06 ± 0.16-0.07 ± 0.16
Anterior Height to Medial Height Ratio (L3)-0.02 ± 0.190.04 ± 0.09
Anterior Height to Medial Height Ratio (L4)0.02 ± 0.12-0.01 ± 0.11
Anterior Height to Medial Height Ratio (L5)-0.02 ± 0.150.04 ± 0.17
Anterior Height to Posterior Height Ratio (L1)-0.03 ± 0.13-0.08 ± 0.17
Anterior Height to Posterior Height Ratio (L2)-0.02 ± 0.13-0.03 ± 0.12
Anterior Height to Posterior Height Ratio (L3)-0.01 ± 0.160.04 ± 0.12
Anterior Height to Posterior Height Ratio (L4)0.03 ± 0.110.02 ± 0.13
Anterior Height to Posterior Height Ratio (L5)0.01 ± 0.130.02 ± 0.15
Medial Height to Posterior Height Ratio (L1)-0.01 ± 0.15-0.04 ± 0.12
Medial Height to Posterior Height Ratio (L2)0.05 ± 0.110.03 ± 0.09
Medial Height to Posterior Height Ratio (L3)-0.02 ± 0.10-0.02 ± 0.10
Medial Height to Posterior Height Ratio (L4)-0.03 ± 0.130.04 ± 0.10
Medial Height to Posterior Height Ratio (L5)0.02 ± 0.16-0.04 ± 0.21
SecondaryChange From Baseline in X-ray of Lumbar Spine Transverse Diameter at Week 52
Time frame:
Baseline to Week 52
Reported as:
Mean · cm
Change From Baseline in X-ray of Lumbar Spine Transverse Diameter at Week 52
cmAll VosoritidePlacebo
Transverse Diameter (L1)0.12 ± 0.170.12 ± 0.11
Transverse Diameter (L2)0.12 ± 0.160.09 ± 0.13
Transverse Diameter (L3)0.08 ± 0.150.09 ± 0.12
Transverse Diameter (L4)0.09 ± 0.130.06 ± 0.11
Transverse Diameter (L5)0.10 ± 0.130.05 ± 0.14
SecondaryChange From Baseline in X-ray of Lumbar Spine Sagittal Width and Week 52

Baseline is defined as Day 1 or screening if a Day 1 assessment is not available.

Time frame:
Baseline to Week 52
Reported as:
Mean · cm
Change From Baseline in X-ray of Lumbar Spine Sagittal Width and Week 52
cmAll VosoritidePlacebo
Sagittal Width (L1)0.07 ± 0.260.00 ± 0.22
Sagittal Width (L2)0.05 ± 0.180.01 ± 0.18
Sagittal Width (L3)0.08 ± 0.200.04 ± 0.19
Sagittal Width (L4)0.16 ± 0.240.03 ± 0.16
Sagittal Width (L5)0.13 ± 0.340.06 ± 0.26
SecondaryChange From Baseline in X-ray of Lumbar Spine Angles at Week 52
Time frame:
Baseline to Week 52
Reported as:
Mean · Degree
Change From Baseline in X-ray of Lumbar Spine Angles at Week 52
DegreeAll VosoritidePlacebo
Sacral Tilt10.6 ± 13.25.7 ± 15.9
Lordosis Angle12.5 ± 17.48.4 ± 14.2
Kyphosis Angle-2.2 ± 13.9-2.1 ± 10.3
SecondaryChanges From Baseline in X-ray of Lumbar Spine Angle Changes: Number of Participants With an Increase in Lumbar Spine Angle at Week 52

Percentages were calculated using the total number of subjects in the safety population (N for each treatment group) as the denominator. All increases are comparing results at Week 52 relative to the baseline assessment.

Time frame:
Baseline to Week 52
Reported as:
Number · Number of participants
Changes From Baseline in X-ray of Lumbar Spine Angle Changes: Number of Participants With an Increase in Lumbar Spine Angle at Week 52
Number of participantsAll VosoritidePlacebo
Increase in sacral tilt (deg) >=5 to <1036
Increase in sacral tilt (deg) >=102410
Increase in lordosis angle (deg) >=5 to <1051
Increase in lordosis angle (deg) >=101914
Increase in kyphosis angle (deg) >=5 to <1032
Increase in kyphosis angle (deg) >=1094
SecondaryMRI Parameter: Change From Baseline to Week 52 for Volume of Face, Sinus, Calvarium, Whole Brain Total Volume, Ventricles Total Volume.
Time frame:
Baseline to Week 52
Reported as:
Mean · cm^3
MRI Parameter: Change From Baseline to Week 52 for Volume of Face, Sinus, Calvarium, Whole Brain Total Volume, Ventricles Total Volume.
cm^3All VosoritidePlacebo
Volume of Face80.527 ± 59.21178.107 ± 33.369
Volume of Sinus2.362 ± 3.5781.195 ± 3.769
Volume of Calvarium213.075 ± 202.415183.427 ± 183.210
Whole Brain Total Volume175.399 ± 158.088146.247 ± 115.274
Ventricles Total Volume11.394 ± 20.4168.515 ± 16.325
SecondaryMRI Parameter: Percentage Change From Baseline to Week 52 for Volume of Face, Sinus, Calvarium, Whole Brain Total Volume, Ventricles Total Volume.
Time frame:
Baseline to Week 52
Reported as:
Mean · percent change
MRI Parameter: Percentage Change From Baseline to Week 52 for Volume of Face, Sinus, Calvarium, Whole Brain Total Volume, Ventricles Total Volume.
percent changeAll VosoritidePlacebo
Volume of Face20.79 ± 18.4619.18 ± 12.22
Volume of sinus72.33 ± 100.9381.97 ± 169.74
Volume of Calvarium19.41 ± 21.7316.50 ± 19.82
Whole Brain Total Volume20.58 ± 21.2916.89 ± 17.22
Ventricles Total Volume33.44 ± 52.6930.85 ± 50.65
SecondaryMRI Parameter: Change From Baseline to Week 52 for Area of Foramen Magnum & Area of Spinal Cord at the Foramen Magnum Level
Time frame:
Baseline to Week 52
Reported as:
Mean · cm^2
MRI Parameter: Change From Baseline to Week 52 for Area of Foramen Magnum & Area of Spinal Cord at the Foramen Magnum Level
cm^2All VosoritidePlacebo
Area of Foramen Magnum0.021 ± 0.3420.060 ± 0.203
Area of Spinal Cord at the Foramen Magnum Level0.011 ± 0.1970.072 ± 0.163
SecondaryMRI Parameter: Percentage Change From Baseline to Week 52 for Area of Foramen Magnum & Area of Spinal Cord at the Foramen Magnum Level
Time frame:
Baseline to Week 52
Reported as:
Mean · Percent change
MRI Parameter: Percentage Change From Baseline to Week 52 for Area of Foramen Magnum & Area of Spinal Cord at the Foramen Magnum Level
Percent changeAll VosoritidePlacebo
Area of Foramen Magnum9.19 ± 47.367.50 ± 19.88
Area of spinal cord at the foramen magnum level7.51 ± 33.1419.60 ± 44.26
SecondaryMRI Parameter: Change From Baseline to Week 52 for Ratio of Face Volume to Calvarium, Ratio of Area of Spinal Cord to Foramen Magnum, Ratio of Face Volume to Sinus
Time frame:
Baseline to Week 52
Reported as:
Mean · Ratio
MRI Parameter: Change From Baseline to Week 52 for Ratio of Face Volume to Calvarium, Ratio of Area of Spinal Cord to Foramen Magnum, Ratio of Face Volume to Sinus
RatioAll VosoritidePlacebo
Ratio of face volume to calvarium0.002 ± 0.0310.003 ± 0.033
Ratio of area of spinal cord to foramen magnum0.005 ± 0.1200.037 ± 0.100
Ratio of face volume to sinus-6.798 ± 175.64614.505 ± 284.950
SecondaryMRI Parameter: Percentage Change From Baseline to Week 52 for Ratio of Face Volume to Calvarium, Ratio of Area of Spinal Cord to Foramen Magnum, Ratio of Face Volume to Sinus
Time frame:
Baseline to Week 52
Reported as:
Mean · Percent change
MRI Parameter: Percentage Change From Baseline to Week 52 for Ratio of Face Volume to Calvarium, Ratio of Area of Spinal Cord to Foramen Magnum, Ratio of Face Volume to Sinus
Percent changeAll VosoritidePlacebo
Ratio of Face Volume to Calvarium0.78 ± 9.061.31 ± 10.07
Ratio of Area of Spinal Cord to Foramen Magnum2.86 ± 23.409.50 ± 22.68
Ratio of face volume to sinus-5.37 ± 60.8392.24 ± 341.33
SecondaryDual X Ray Absorptiometry (DEXA) Parameter: Change From Baseline to Week 52 for Whole Body Less Head Bone Mineral Content (BMC)
Time frame:
Baseline to Week 52
Reported as:
Mean · gm
Dual X Ray Absorptiometry (DEXA) Parameter: Change From Baseline to Week 52 for Whole Body Less Head Bone Mineral Content (BMC)
gmAll VosoritidePlacebo
GE - Lunar Prodigy: Whole Body Less Head BMC55.87 ± 14.6850.26 ± 17.44
Hologic Discovery Horizon Whole Body Less Head BMC44.61 ± 12.6247.19 ± 12.55
SecondaryDEXA Parameter: Change From Baseline to Week 52 of Whole Body Less Head Bone Mineral Density (BMD)
Time frame:
Baseline to Week 52
Reported as:
Mean · g/cm^2
DEXA Parameter: Change From Baseline to Week 52 of Whole Body Less Head Bone Mineral Density (BMD)
g/cm^2All VosoritidePlacebo
GE - Lunar Prodigy Whole Body Less Head BMD0.04 ± 0.020.05 ± 0.03
Hologic Discovery Horizon Whole Body Less Head BMD0.03 ± 0.010.04 ± 0.02
SecondaryDEXA Parameter: Change From Baseline to Week 52 of Whole Body BMC
Time frame:
Baseline to Week 52
Reported as:
Mean · gm
DEXA Parameter: Change From Baseline to Week 52 of Whole Body BMC
gmAll VosoritidePlacebo
GE - Lunar Prodigy Whole Body BMC96.85 ± 39.8298.99 ± 32.45
Hologic - Discovery Horizon Whole Body BMC87.97 ± 32.35101.33 ± 33.34
SecondaryDEXA Parameter: Change From Baseline to Week 52 of Lumbar Spine BMC
Time frame:
Baseline to Week 52
Reported as:
Mean · gm
DEXA Parameter: Change From Baseline to Week 52 of Lumbar Spine BMC
gmAll VosoritidePlacebo
GE - Lunar Prodigy Lumbar Spine BMC2.73 ± 0.832.09 ± 0.97
Hologic - Discovery Horizon Lumbar Spine BMC2.19 ± 0.681.94 ± 0.72
SecondaryDEXA Parameter: Change From Baseline to Week 52 of Whole Body BMD
Time frame:
Baseline to Week 52
Reported as:
Mean · g/cm^2
DEXA Parameter: Change From Baseline to Week 52 of Whole Body BMD
g/cm^2All VosoritidePlacebo
GE - Lunar Prodigy Whole Body BMD0.06 ± 0.060.07 ± 0.04
Hologic - Discovery Horizon Whole Body BMD0.05 ± 0.020.07 ± 0.03
SecondaryDEXA Parameter: Change From Baseline to Week 52 of Lumbar Spine BMD
Time frame:
Baseline to Week 52
Reported as:
Mean · g/cm^2
DEXA Parameter: Change From Baseline to Week 52 of Lumbar Spine BMD
g/cm^2All VosoritidePlacebo
GE - Lunar Prodigy Lumbar Spine BMD0.07 ± 0.040.05 ± 0.03
Hologic - Discovery Horizon Lumbar Spine BMD0.05 ± 0.030.06 ± 0.04
SecondaryChange From Baseline to Week 52 in Whole Body BMD Z-score

Hologic - Discovery Horizon Whole Body BMD Z-Score. Change in whole body bone mineral density (BMD) Z-score from baseline at 52 weeks indicates whether there has been a positive or negative change in BMD using a z-score generated by converting the participants BMD to an age and sex appropriate standard deviation score (SDS) by comparison with an average stature reference population. A whole body BMD Z-score \<-2 SD can indicate low bone density in children. The Whole Body BMD (bone mineral density) z-score compares the BMD to the average bone density of people of the same age, and sex as a comparator. A Z-score less than 0 means that the participant has a lower BMD than people in the same age and sex group, and could indicate a risk of osteopenia or osteoporosis.

Time frame:
Baseline to Week 52
Reported as:
Mean · Z-score
Change From Baseline to Week 52 in Whole Body BMD Z-score
Z-scoreAll VosoritidePlacebo
Change From Baseline to Week 52 in Whole Body BMD Z-score-0.20 ± 0.350.30 ± 0.47
SecondaryChange From Baseline to Week 52 in Lumbar Spine BMD Z-Score

Hologic - Discovery Horizon Lumbar Spine BMD Z-Score Change in lumbar spine bone mineral density (BMD) Z-score from baseline at 52 weeks indicates whether there has been a positive or negative change in BMD using a z-score generated by converting the participants lumbar spine BMD to an age and sex appropriate standard deviation score (SDS) by comparison with an average stature reference population. A BMD Z-score \<-2 SD can indicate low bone density in the lumbar spine in children. The Lumbar Spine BMD (bone mineral density) z-score compares the BMD in the lumbar spine to the average spinal bone density of people of the same age, and sex as a comparator. A Z-score less than 0 means that the participant has a lower BMD than people in the same age and sex group, and could indicate a risk of osteopenia or osteoporosis of the spine.

Time frame:
Baseline to Week 52
Reported as:
Mean · Z-score
Change From Baseline to Week 52 in Lumbar Spine BMD Z-Score
Z-scoreAll VosoritidePlacebo
Change From Baseline to Week 52 in Lumbar Spine BMD Z-Score0.17 ± 0.240.03 ± 0.45
SecondaryImmunogenicity: Number of Participants With Incidence of Antibody Positivity at Scheduled Visits

Number of participants with Incidence of Antibody Positivity at Scheduled Visits for : total antibody (TAb), Neutralizing antibodies (NAb), atrial natriuretic peptide (ANP), B-type Natriuretic Peptide (BNP) \& C-type natriuretic peptide (CNP). TAb Titer Positive, NAb Titer Positive, ANP Reactivity Positive, BNP Reactivity Positive \& CNP Reactivity Positive. Day 1 is the baseline assessment result taken prior to first dose of study drug. Ever Positive = the number of participants with at least one positive sample result.

Time frame:
At Day 1, Week 3, Week 13, Week 26, Week 52, & Ever Positive.
Reported as:
Number · participants
Immunogenicity: Number of Participants With Incidence of Antibody Positivity at Scheduled Visits
participantsAll VosoritidePlacebo
TAb Titer Positive: Day 100
TAb Titer Positive: Week 300
TAb Titer Positive: Week 1300
TAb Titer Positive: Week 2620
TAb Titer Positive: Week 5280
TAb Titer Ever Positive80
NAb Titer Positive: Day 100
NAb Titer Positive: Week 300
NAb Titer Positive: Week 1300
NAb Titer Positive: Week 2600
NAb Titer Positive: Week 5200
NAb Titer Ever Positive00
ANP Reactivity Positive: Day 135
ANP Reactivity Positive: Week 300
ANP Reactivity Positive: Week 1310
ANP Reactivity Positive: Week 2660
ANP Reactivity Positive: Week 52110
ANP Reactivity Ever Positive120
BNP Reactivity Positive: Day 103
BNP Reactivity Positive: Week 300
BNP Reactivity Positive: Week 1320
BNP Reactivity Positive: Week 2630
BNP Reactivity Positive: Week 5220
BNP Reactivity Ever Positive30
CNP Reactivity Positive: Day 101
CNP Reactivity Positive: Week 300
CNP Reactivity Positive: Week 1310
CNP Reactivity Positive: Week 2620
CNP Reactivity Positive: Week 5240
CNP Reactivity Ever Positive40
SecondaryBiomarker: Bone Specific Alkaline Phosphatase (BSAP) Overtime
Time frame:
At Baseline, Day 8, Week 6, Week 20, & Week 39.
Reported as:
Mean · U/L
Biomarker: Bone Specific Alkaline Phosphatase (BSAP) Overtime
U/LAll VosoritidePlacebo
BSAP: Baseline140.28 ± 183.23113.43 ± 33.56
BSAP: Day 8122.32 ± 99.09104.12 ± 29.12
BSAP: Change from baseline to Day 8-19.39 ± 202.90-7.67 ± 17.53
BSAP: Week 6130.38 ± 140.08109.46 ± 29.04
BSAP: Change from baseline to Week 62.63 ± 218.60-6.17 ± 24.32
BSAP: Week 20109.67 ± 30.88104.46 ± 29.69
BSAP: Change from baseline to Week 20-7.21 ± 96.94-11.32 ± 18.19
BSAP: Week 39108.49 ± 32.02208.13 ± 363.56
BSAP: Change from baseline to Week 39-12.21 ± 105.0495.41 ± 352.78
SecondaryBiomarker: Type II Collagen C-Telopeptides Normalized for Creatinine (CTX-II)
Time frame:
Baseline to Week 52.
Reported as:
Mean · ng/ mmol Cr
Biomarker: Type II Collagen C-Telopeptides Normalized for Creatinine (CTX-II)
ng/ mmol CrAll VosoritidePlacebo
Biomarker: Type II Collagen C-Telopeptides Normalized for Creatinine (CTX-II)-9364.7 ± 65244.1-7607.6 ± 54614.9
SecondaryBiomarker: Plasma Cyclic Guanosine Monophosphate (cGMP) Change From Pre-Dose to Maximum Post-Dose at Week 52
Time frame:
Week 52 Pre-Dose to Week 52 Maximum Post-Dose.
Reported as:
Mean · nM
Biomarker: Plasma Cyclic Guanosine Monophosphate (cGMP) Change From Pre-Dose to Maximum Post-Dose at Week 52
nMAll VosoritidePlacebo
Biomarker: Plasma Cyclic Guanosine Monophosphate (cGMP) Change From Pre-Dose to Maximum Post-Dose at Week 5239.079 ± 25.7069.460 ± 26.307
SecondaryBiomarker: Bone and Collagen Metabolism Biomarker Over Time-CNP Col X BM

Laboratory results up to 30 days after study drug discontinuation were included. Baseline is the last measurement prior to the initiation of study drug.

Time frame:
At Baseline, Day 8, Week 6, Week 20, & Week 39.
Reported as:
Mean · pg/mL
Biomarker: Bone and Collagen Metabolism Biomarker Over Time-CNP Col X BM
pg/mLAll VosoritidePlacebo
CNP Col X BM: Baseline9833.8 ± 3444.79555.0 ± 4016.7
CNP Col X BM: Day 812093.8 ± 4443.810017.5 ± 3831.2
CNP Col X BM: Change from baseline to Day 82139.5 ± 3871.91391.3 ± 3354.2
CNP Col X BM: Week 613456.3 ± 4763.39464.8 ± 4243.3
CNP Col X BM: Change from baseline to Week 63400.3 ± 4554.6200.3 ± 3867.5
CNP Col X BM: Week 2012833.3 ± 4581.912064.8 ± 5277.3
CNP Col X BM: Change from baseline to Week 202928.0 ± 4385.92435.5 ± 4666.9
CNP Col X BM: Week 3912249.7 ± 5056.59932.7 ± 4004.4
CNP Col X BM: Change from baseline to Week 392362.8 ± 5752.9946.4 ± 3490.1
SecondaryChange in Sleep Study Indices at Week 52

Sleep-testing device was used to assess presence \& severity of sleep-disordered breathing by measurement of blood oxygen(O2)saturation,pulse rate,\& airflow during overnight monitoring Episodes(Epi) of sleep apnea variables summarized as: Number(No.)of epi of apnea/hr(AI);No.of epi of hypopnea/hr(HI);No.of epi of obstructive apnea hypopneas/hr(AHI);No.of epi of obstructive apneas/hr(Obstructive Apnea Index);No.of epi of central apneas/hr(CAI);No.of desaturations/hr \>=3% AHI is a marker of obstructive sleep apnea (OSA), scored as No.of apnea or hypopnea epi/hr, with AHI \<=1/hr normal, 1\< AHI\<=5 mild,5\< AHI \<=10 moderate,\& AHI\>10/hr severe OSA. CAI reflects cervical cord compression at cervical-medullary junction, \& is No. of epi of a pause in ventilation with no associated respiratory effort, with\> 5 epi/hr abnormal.O2 desaturation index measures average No. of desaturation epi/hr, defined as decrease in O2 saturation of \>=3% for at least 10sec, with(\<8/hr normal \& \>=8/hr abnormal

Time frame:
Baseline to Week 52
Reported as:
Mean · Events per hour
Change in Sleep Study Indices at Week 52
Events per hourCohort 1: PlaceboCohort 1: VosoritideCohort 2: PlaceboCohort 2: VosoritideCohort 3: PlaceboCohort 3: Vosoritide
Apnea Hypopnea Index (AHI)-0.54 ± 2.70-1.45 ± 4.631.06 ± 4.80-0.72 ± 1.411.89 ± 6.31-0.94 ± 2.78
Apnea Index (AI)-1.07 ± 2.12-0.83 ± 1.930.40 ± 2.34-0.71 ± 1.61-1.09 ± 1.22-0.36 ± 2.54
Central Apnea Index (CAI)-1.26 ± 2.66-0.74 ± 1.86-0.28 ± 0.89-0.71 ± 1.61-1.00 ± 0.970.50 ± 0.92
Hypopnea Index (HI)0.52 ± 1.35-0.61 ± 3.630.66 ± 2.53-0.01 ± 1.322.97 ± 5.45-0.56 ± 0.54
Desaturation per Hour >=3%-0.41 ± 1.51-1.24 ± 3.980.98 ± 3.60-0.69 ± 1.301.71 ± 6.63-0.93 ± 2.60
Obstructive Index0.19 ± 0.73-0.09 ± 0.450.68 ± 1.52-0.01 ± 0.08-0.07 ± 0.64-0.86 ± 2.08
SecondaryPK Parameter: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-∞) at Day1, Week 13, Week 26, Week 39, & Week 52

Vosoritide concentrations at 5-, 15- and 30-minute post-dose for one participant on Day 1 were not available, hence PK parameters for this participant were excluded from summary statistics. PK parameters for another participant on Day 1 obtained from extrapolation. AUC0-∞ excluded from summary statistics. PK parameters are not available for this participant at Week 13 due to unsuccessful venipuncture, and Week 26 as post-dose PK samples were not collected.

Time frame:
At Day1, Week 13, Week 26, Week 39, & Week 52.
Reported as:
Mean · min*pg/ml
PK Parameter: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-∞) at Day1, Week 13, Week 26, Week 39, & Week 52
min*pg/mlAll Vosoritide
Cohort 1 15 μg/kg/day: Day 01149000 ± 98000
Cohort 1 15 μg/kg/day: Week 13197000 ± 144000
Cohort 1 15 μg/kg/day: Week 26306000 ± 252000
Cohort 1 15 μg/kg/day: Week 39284000 ± 137000
Cohort 1 15 μg/kg/day: Week 52303000 ± 208000
Cohort 2 15 μg/kg/day: Day 01102000 ± NA
Cohort 2 15 μg/kg/day: Week 1374500 ± NA
Cohort 2 15 μg/kg/day: Week 26233000 ± 132000
Cohort 2 15 μg/kg/day: Week 39204000 ± 39700
Cohort 2 15 μg/kg/day: Week 52137000 ± 48900
Cohort 2 30 μg/kg/day: Day 01557000 ± 278000
Cohort 2 30 μg/kg/day: Week 13670000 ± 312000
Cohort 2 30 μg/kg/day: Week 26429000 ± 163000
Cohort 2 30 μg/kg/day: Week 39387000 ± 53800
Cohort 2 30 μg/kg/day: Week 52768000 ± 391000
Cohort 3 30 μg/kg/day: Day 01353000 ± 133000
Cohort 3 30 μg/kg/day: Week 13382000 ± 268000
Cohort 3 30 μg/kg/day: Week 26305000 ± 82100
Cohort 3 30 μg/kg/day: Week 39575000 ± 455000
Cohort 3 30 μg/kg/day: Week 52622000 ± 455000
SecondaryPK Parameter: Area Under the Plasma Concentration-time Curve From Time 0 to Nominal 120 Minutes Postdose (AUC 0- 120 Min) at Day 01, Week 13, Week 26, Week 39, & Week 52
Time frame:
At Day 01, Week 13, Week 26, Week 39, & Week 52
Reported as:
Mean · min*pg/ml
PK Parameter: Area Under the Plasma Concentration-time Curve From Time 0 to Nominal 120 Minutes Postdose (AUC 0- 120 Min) at Day 01, Week 13, Week 26, Week 39, & Week 52
min*pg/mlAll Vosoritide
Cohort 1 15 μg/kg/day: Day 01134000 ± 96500
Cohort 1 15 μg/kg/day: Week 13183000 ± 126000
Cohort 1 15 μg/kg/day: Week 26283000 ± 222000
Cohort 1 15 μg/kg/day: Week 39257000 ± 132000
Cohort 1 15 μg/kg/day: Week 52260000 ± 172000
Cohort 2 15 μg/kg/day: Day 0183100 ± 48300
Cohort 2 15 μg/kg/day: Week 13115000 ± 59300
Cohort 2 15 μg/kg/day: Week 26197000 ± 121000
Cohort 2 15 μg/kg/day: Week 39166000 ± 81000
Cohort 2 15 μg/kg/day: Week 52125000 ± 76700
Cohort 2 30 μg/kg/day: Day 01525000 ± 251000
Cohort 2 30 μg/kg/day: Week 13642000 ± 353000
Cohort 2 30 μg/kg/day: Week 26408000 ± 148000
Cohort 2 30 μg/kg/day: Week 39365000 ± 44700
Cohort 2 30 μg/kg/day: Week 52670000 ± 335000
Cohort 3 30 μg/kg/day: Day 01312000 ± 119000
Cohort 3 30 μg/kg/day: Week 13342000 ± 245000
Cohort 3 30 μg/kg/day: Week 26300000 ± 79100
Cohort 3 30 μg/kg/day: Week 39591000 ± 359000
Cohort 3 30 μg/kg/day: Week 52558000 ± 400000
SecondaryPK Parameter: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of Last Measurable Concentration (AUC0-t) at Day 01, Week 13, Week 26, Week 39, & Week 52
Time frame:
At Day 01, Week 13, Week 26, Week 39, & Week 52
Reported as:
Mean · min*pg/ml
PK Parameter: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of Last Measurable Concentration (AUC0-t) at Day 01, Week 13, Week 26, Week 39, & Week 52
min*pg/mlAll Vosoritide
Cohort 1 15 μg/kg/day: Day 01132000 ± 97300
Cohort 1 15 μg/kg/day: Week 13182000 ± 127000
Cohort 1 15 μg/kg/day: Week 26282000 ± 222000
Cohort 1 15 μg/kg/day: Week 39256000 ± 132000
Cohort 1 15 μg/kg/day: Week 52258000 ± 169000
Cohort 2 15 μg/kg/day: Day 0165900 ± 33600
Cohort 2 15 μg/kg/day: Week 13112000 ± 62900
Cohort 2 15 μg/kg/day: Week 26196000 ± 121000
Cohort 2 15 μg/kg/day: Week 39165000 ± 82400
Cohort 2 15 μg/kg/day: Week 52122000 ± 75700
Cohort 2 30 μg/kg/day: Day 01547000 ± 279000
Cohort 2 30 μg/kg/day: Week 13645000 ± 357000
Cohort 2 30 μg/kg/day: Week 26407000 ± 148000
Cohort 2 30 μg/kg/day: Week 39365000 ± 44300
Cohort 2 30 μg/kg/day: Week 52672000 ± 334000
Cohort 3 30 μg/kg/day: Day 01323000 ± 129000
Cohort 3 30 μg/kg/day: Week 13340000 ± 244000
Cohort 3 30 μg/kg/day: Week 26297000 ± 80700
Cohort 3 30 μg/kg/day: Week 39567000 ± 361000
Cohort 3 30 μg/kg/day: Week 52557000 ± 401000
SecondaryPK Parameter: Maximum Observed Plasma Concentration (Cmax) at Day 01, Week 13, Week 26, Week 39, & Week 52
Time frame:
At Day 01, Week 13, Week 26, Week 39, & Week 52
Reported as:
Mean · pg/ml
PK Parameter: Maximum Observed Plasma Concentration (Cmax) at Day 01, Week 13, Week 26, Week 39, & Week 52
pg/mlAll Vosoritide
Cohort 1 15 μg/kg/day: Day 014430 ± 3670
Cohort 1 15 μg/kg/day: Week 134350 ± 1670
Cohort 1 15 μg/kg/day: Week 265850 ± 3260
Cohort 1 15 μg/kg/day: Week 395600 ± 2200
Cohort 1 15 μg/kg/day: Week 525640 ± 2740
Cohort 2 15 μg/kg/day: Day 012840 ± 1230
Cohort 2 15 μg/kg/day: Week 135970 ± 2390
Cohort 2 15 μg/kg/day: Week 266800 ± 3360
Cohort 2 15 μg/kg/day: Week 394600 ± 2150
Cohort 2 15 μg/kg/day: Week 523870 ± 2120
Cohort 2 30 μg/kg/day: Day 0114500 ± 5950
Cohort 2 30 μg/kg/day: Week 1313400 ± 6070
Cohort 2 30 μg/kg/day: Week 2610100 ± 2970
Cohort 2 30 μg/kg/day: Week 396980 ± 1140
Cohort 2 30 μg/kg/day: Week 5212900 ± 6260
Cohort 3 30 μg/kg/day: Day 0113400 ± 5710
Cohort 3 30 μg/kg/day: Week 1310500 ± 6850
Cohort 3 30 μg/kg/day: Week 2611500 ± 4290
Cohort 3 30 μg/kg/day: Week 3918400 ± 11900
Cohort 3 30 μg/kg/day: Week 5213500 ± 6770
SecondaryPK Parameter: Time to Reach Maximum Concentration (Tmax) at Day 01, Week 13, Week 26, Week 39, & Week 52
Time frame:
At Day 01, Week 13, Week 26, Week 39, & Week 52.
Reported as:
Mean · min
PK Parameter: Time to Reach Maximum Concentration (Tmax) at Day 01, Week 13, Week 26, Week 39, & Week 52
minAll Vosoritide
Cohort 1 15 μg/kg/day: Day 0113.1 ± 6.33
Cohort 1 15 μg/kg/day: Week 1314.3 ± 5.5
Cohort 1 15 μg/kg/day: Week 2616.1 ± 8.69
Cohort 1 15 μg/kg/day: Week 3917.4 ± 11.9
Cohort 1 15 μg/kg/day: Week 5216.1 ± 6.27
Cohort 2 15 μg/kg/day: Day 0111.3 ± 6.35
Cohort 2 15 μg/kg/day: Week 136 ± 1.41
Cohort 2 15 μg/kg/day: Week 2610.8 ± 5.5
Cohort 2 15 μg/kg/day: Week 3915.4 ± 11.6
Cohort 2 15 μg/kg/day: Week 5214.2 ± 5.76
Cohort 2 30 μg/kg/day: Day 0112.9 ± 9.1
Cohort 2 30 μg/kg/day: Week 1314 ± 8.42
Cohort 2 30 μg/kg/day: Week 2612 ± 5.2
Cohort 2 30 μg/kg/day: Week 3915 ± 0
Cohort 2 30 μg/kg/day: Week 5214.3 ± 1.53
Cohort 3 30 μg/kg/day: Day 017.36 ± 3.53
Cohort 3 30 μg/kg/day: Week 139.43 ± 5.22
Cohort 3 30 μg/kg/day: Week 269 ± 4.69
Cohort 3 30 μg/kg/day: Week 3911.3 ± 3.59
Cohort 3 30 μg/kg/day: Week 5214.5 ± 3.51
SecondaryPK Parameter: Apparent Clearance (CL/F) at Day 01, Week 13, Week 26, Week 39, & Week 52

Vosoritide concentrations at 5-, 15- and 30-minute post-dose for one participant on Day 1 were not available, hence PK parameters for this participant were excluded from summary statistics. PK parameters for another participant on Day 1 obtained from extrapolation. AUC0-∞, CL/F, V/F and t1/2 excluded from summary statistics. PK parameters are not available for this participant at Week 13 due to unsuccessful venipuncture, and Week 26 as post-dose PK samples were not collected.

Time frame:
At Day 01, Week 13, Week 26, Week 39, & Week 52.
Reported as:
Mean · ml/min/kg
PK Parameter: Apparent Clearance (CL/F) at Day 01, Week 13, Week 26, Week 39, & Week 52
ml/min/kgAll Vosoritide
Cohort 1 15 μg/kg/day: Day 01134 ± 59.8
Cohort 1 15 μg/kg/day: Week 13111 ± 58.5
Cohort 1 15 μg/kg/day: Week 2679.8 ± 48.3
Cohort 1 15 μg/kg/day: Week 3965.3 ± 32.7
Cohort 1 15 μg/kg/day: Week 5269 ± 41.2
Cohort 2 15 μg/kg/day: Day 1147 ± NA
Cohort 2 15 μg/kg/day: Week 13201 ± NA
Cohort 2 15 μg/kg/day: Week 2679.5 ± 38.4
Cohort 2 15 μg/kg/day: Week 3975.5 ± 14.8
Cohort 2 15 μg/kg/day: Week 52122 ± 52.5
Cohort 2 30 μg/kg/day: Day 0165.9 ± 31.6
Cohort 2 30 μg/kg/day: Week 1358.7 ± 40.4
Cohort 2 30 μg/kg/day: Week 2679.4 ± 37.7
Cohort 2 30 μg/kg/day: Week 3978.3 ± 10.9
Cohort 2 30 μg/kg/day: Week 5249.7 ± 32
Cohort 3 30 μg/kg/day: Day 0195.9 ± 34
Cohort 3 30 μg/kg/day: Week 13115 ± 78.1
Cohort 3 30 μg/kg/day: Week 26104 ± 23.2
Cohort 3 30 μg/kg/day: Week 3973.6 ± 41.6
Cohort 3 30 μg/kg/day: Week 5276.5 ± 49.8
SecondaryPK Parameter: Apparent Volume of Distribution (Vz/F) at Day 01, Week 13, Week 26, Week 39, & Week 52

Vosoritide concentrations at 5-, 15- and 30-minute post-dose for one participant on Day 1 were not available, hence PK parameters for this participant were excluded from summary statistics. PK parameters for another participant on Day 1 obtained from extrapolation. V/F excluded from summary statistics. PK parameters are not available for this participant at Week 13 due to unsuccessful venipuncture, and Week 26 as post-dose PK samples were not collected.

Time frame:
At Day 01, Week 13, Week 26, Week 39, & Week 52.
Reported as:
Mean · ml/kg
PK Parameter: Apparent Volume of Distribution (Vz/F) at Day 01, Week 13, Week 26, Week 39, & Week 52
ml/kgAll Vosoritide
Cohort 1 15 μg/kg/day: Day 014070 ± 2310
Cohort 1 15 μg/kg/day: Week 133990 ± 2960
Cohort 1 15 μg/kg/day: Week 263400 ± 2520
Cohort 1 15 μg/kg/day: Week 392330 ± 1150
Cohort 1 15 μg/kg/day: Week 522660 ± 1420
Cohort 2 15 μg/kg/day: Day 015550 ± NA
Cohort 2 15 μg/kg/day: Week 137810 ± NA
Cohort 2 15 μg/kg/day: Week 263890 ± 2880
Cohort 2 15 μg/kg/day: Week 392250 ± 284
Cohort 2 15 μg/kg/day: Week 523770 ± 1410
Cohort 2 30 μg/kg/day: Day 013190 ± 1790
Cohort 2 30 μg/kg/day: Week 132090 ± 1360
Cohort 2 30 μg/kg/day: Week 261960 ± 829
Cohort 2 30 μg/kg/day: Week 392920 ± 205
Cohort 2 30 μg/kg/day: Week 523040 ± 2630
Cohort 3 30 μg/kg/day: Day 015240 ± 1890
Cohort 3 30 μg/kg/day: Week 134260 ± 2960
Cohort 3 30 μg/kg/day: Week 262750 ± 710
Cohort 3 30 μg/kg/day: Week 392200 ± 951
Cohort 3 30 μg/kg/day: Week 522620 ± 1950
SecondaryPK Parameter: Elimination Half-life (t1/2) at Day 01, Week 13, Week 26, Week 39, & Week 52

Vosoritide concentrations at 5-, 15- and 30-minute post-dose for one participant on Day 1 were not available, hence PK parameters for this participant were excluded from summary statistics. PK parameters for another participant on Day 1 obtained from extrapolation. AUC0-∞, CL/F, V/F and t1/2 excluded from summary statistics. PK parameters are not available for this participant at Week 13 due to unsuccessful venipuncture, and Week 26 as post-dose PK samples were not collected.

Time frame:
At Day 01, Week 13, Week 26, Week 39, & Week 52.
Reported as:
Mean · min
PK Parameter: Elimination Half-life (t1/2) at Day 01, Week 13, Week 26, Week 39, & Week 52
minAll Vosoritide
Cohort 1 15 μg/kg/day: Day 0121.7 ± 7.99
Cohort 1 15 μg/kg/day: Week 1325.4 ± 10.7
Cohort 1 15 μg/kg/day: Week 2629.2 ± 7.06
Cohort 1 15 μg/kg/day: Week 3925.7 ± 7.82
Cohort 1 15 μg/kg/day: Week 5229 ± 9.12
Cohort 2 15 μg/kg/day: Day 0126.1 ± NA
Cohort 2 15 μg/kg/day: Week 1326.9 ± NA
Cohort 2 15 μg/kg/day: Week 2632.7 ± 9.62
Cohort 2 15 μg/kg/day: Week 3920.9 ± 2.18
Cohort 2 15 μg/kg/day: Week 5224 ± 12.8
Cohort 2 30 μg/kg/day: Day 0133.3 ± 8.41
Cohort 2 30 μg/kg/day: Week 1325.6 ± 3.59
Cohort 2 30 μg/kg/day: Week 2621 ± 13.1
Cohort 2 30 μg/kg/day: Week 3926.2 ± 5.46
Cohort 2 30 μg/kg/day: Week 5240.1 ± 15.2
Cohort 3 30 μg/kg/day: Day 0141.1 ± 18.8
Cohort 3 30 μg/kg/day: Week 1326.2 ± 7.1
Cohort 3 30 μg/kg/day: Week 2619.2 ± 6.14
Cohort 3 30 μg/kg/day: Week 3922.7 ± 5.36
Cohort 3 30 μg/kg/day: Week 5224.3 ± 6.58

Adverse events

Collected over Up to Week 56 Safety Follow-Up.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/32 (0%)6/32 (18.8%)32/32 (100%)
Vosoritide1/43 (2.3%)3/43 (7%)43/43 (100%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventPlaceboVosoritide
Petit mal epilepsyNervous system disorders1/320/43
GastroenteritisInfections and infestations1/320/43
Autism spectrum disordePsychiatric disorders1/320/43
Otitis mediaInfections and infestations1/320/43
Parainfluenzae virus infectionInfections and infestations1/320/43
VomitingGastrointestinal disorders1/320/43
Skull fractureInjury, poisoning and procedural complications1/320/43
Respiratory distressRespiratory, thoracic and mediastinal disorders1/320/43
Oxygen saturation decreasedInvestigations0/321/43
PneumoniaInfections and infestations0/321/43
Most frequent other events
Showing 10 of 15
Most frequent other events
EventPlaceboVosoritide
Injection site reactionGeneral disorders13/3234/43
Injection site erythemaGeneral disorders13/3233/43
Viral infectionInfections and infestations4/328/43
Injection site swellingGeneral disorders2/328/43
FallInjury, poisoning and procedural complications3/327/43
Injection site urticariaGeneral disorders1/326/43
Arthropod biteInjury, poisoning and procedural complications2/326/43
Injection site indurationGeneral disorders0/325/43
ConstipationGastrointestinal disorders2/325/43
RhinitisInfections and infestations0/324/43

Baseline characteristics

FAS Population: The Full Analysis Set (FAS) was defined according to the intent-to-treat principle and included all enrolled sentinel and randomized participants with a signed informed consent.

Age, Continuous
Age, Continuous(Months)SentinelRandomized VosoritideRandomized PlaceboTotal
Mean23.4 ± 21.023.0 ± 16.926.5 ± 19.324.5 ± 18.4
Age, Continuous
Age, Continuous(Months)SentinelRandomized VosoritideRandomized PlaceboTotal
Mean24.71 ± 20.7924.39 ± 16.8327.82 ± 19.2525.90 ± 18.30
Sex: Female, Male
Sex: Female, Male(Participants)SentinelRandomized VosoritideRandomized PlaceboTotal
Female3151937
Male8171338
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SentinelRandomized VosoritideRandomized PlaceboTotal
Hispanic or Latino0336
Not Hispanic or Latino11292969
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)SentinelRandomized VosoritideRandomized PlaceboTotal
White8212554
Asian-Other1629
Asian-Japanese0448
Multiple2103
Native Hawaiian or Other Pacific Islander0011
Weight
Weight(Kg)SentinelRandomized VosoritideRandomized PlaceboTotal
Mean10.12 ± 3.7010.20 ± 3.8310.55 ± 4.3110.34 ± 3.98
Weight Z-Score
Weight Z-Score(Z-Score)SentinelRandomized VosoritideRandomized PlaceboTotal
Mean-1.41 ± 0.73-1.49 ± 1.26-1.59 ± 1.44-1.52 ± 1.27
BMI
BMI(kg/m^2)SentinelRandomized VosoritideRandomized PlaceboTotal
Mean20.06 ± 1.8719.48 ± 2.4520.14 ± 2.3919.85 ± 2.34

1 further baseline measures are reported on the registry.

08

Study locations

16 sites
  • Children's Hospital & Research Center Oakland
    Oakland, California 94609, United States
  • Harbor - UCLA Medical Center
    Torrance, California 90509, United States
  • Alfred I. duPont Hospital for Children
    Wilmington, Delaware 19803, United States
  • Emory University
    Decatur, Georgia 30033, United States
  • Ann and Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232-2578, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Medical College of Wisconsin, Children's Hospital
    Milwaukee, Wisconsin 53226, United States
  • The Children's Hospital at Westmead
    Westmead, New South Wales 2145, Australia
  • Murdoch Children's Research Institute
    Parkville, Victoria 3052, Australia
  • Osaka University Hospital
    Osaka, Japan
  • Saitama Children's Medical Center
    Saitama, Japan
  • Tokushima University Hospital
    Tokushima, Japan
  • Guy's and St. Thomas NHS Foundation Trust Evelina Children's Hospital
    London, SE1 9RT, United Kingdom
  • Sheffield Children's NHS Foundation Trust
    Sheffield, S10 2TH, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2018 to primary completion in Jan 2022, 43 months.

Results were first posted in Jun 2024, 2 years 4 months after primary completion. A results delay was requested in Dec 2022.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2018
First posted
Jul 11, 2018
StartActual
Jun 13, 2018
Primary completionActual
Jan 26, 2022
CompletionActual
Jan 26, 2022
Results delay requested
Dec 15, 2022
Results first posted
Jun 13, 2024
Last update
Jun 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03583697
Responsible party
Sponsor
First posted
Jul 11, 2018
Start date
Jun 13, 2018
Primary completion
Jan 26, 2022
Completion
Jan 26, 2022
Results posted
Jun 13, 2024
Last update
Jun 13, 2024

Study contacts

Medical Director, MD
study director · BioMarin Pharmaceutical

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vosoritide

Start the discussion